metformin has been researched along with Metabolic Syndrome in 277 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 9.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "To evaluate the effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome that are in menopausal transition." | 9.34 | Effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome: A randomized placebo-controlled trial. ( Dangrat, C; Indhavivadhana, S; Jirattigalachote, A; Rattanachaiyanont, M; Techatraisak, K; Wongwananurak, T, 2020) |
| "We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome." | 9.34 | Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. ( Cha, BS; Choi, DS; Choi, KM; Chun, SW; Kim, DM; Kim, KJ; Kim, MK; Kim, SG; Lee, HW; Lim, S; Mok, JO; Park, KS; Seo, JA; Shon, HS; Yoon, KH, 2020) |
| "Metformin treatment (1000-2000 mg/day) over 6 months in pubertal children and/or adolescents with obesity and hyperinsulinism is associated with a reduction in body mass index (BMI) and the insulin resistance index (HOMA-IR)." | 9.30 | Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Dorado-Ceballos, E; Ibáñez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Osiniri, I; Prats-Puig, A; Xargay-Torrent, S, 2019) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 9.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 9.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 9.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months." | 9.20 | Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. ( Cypess, AM; Fitch, KV; Grinspoon, SK; Petrow, E; Srinivasa, S; Torriani, M; Wei, J; Wong, K, 2015) |
| "This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT)." | 9.20 | Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. ( Chen, M; Chen, Y; Dai, Y; Li, Y; Wang, Y; Xie, H; Zhao, X, 2015) |
| "The present study tested the hypothesis that pretreatment with metformin decreases postprocedural myocardial injury and improves clinical outcomes in metabolic syndrome patients following percutaneous coronary intervention (PCI)." | 9.19 | Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. ( Li, J; Song, SJ; Sun, XJ; Xu, JP; Xu, ZW; Zhao, XZ, 2014) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 9.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 9.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 9.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "In a subanalysis on the metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome (MEFISTO)(8) (an open-label fashion, with 1 year of 850 mg daily of metformin) subjects' samples, we measured the paraoxonase 1 (PON1) activity in 39 patients that finished the study and relate values with high density lipoprotein (HDL)." | 9.16 | Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study. ( Ceballos, G; Guzmán-Grenfell, M; Hicks, JJ; Meaney, A; Meaney, E; Olivares-Corichi, I; Ramírez-Sánchez, I; Sierra-Vargas, P, 2012) |
| "To examine the appropriate treatment of oligo-terato-asthenozoospermic patients with metabolic syndrome, 45 patients were treated with metformin for 6 months." | 9.15 | Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome. ( De Leo, V; Morgante, G; Musacchio, MC; Orvieto, R; Piomboni, P; Tosti, C, 2011) |
| "To test whether a portion control diet could prevent weight gain during treatment with pioglitazone in patients with type 2 diabetes mellitus (T2DM)." | 9.14 | Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. ( Bray, GA; Greenway, FL; Gupta, AK; Smith, SR, 2009) |
| "To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen." | 9.14 | Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen ( Bouskela, E; Kraemer-Aguiar, LG; Lima, LM; Wiernsperger, N, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome." | 9.14 | Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. ( Hayakawa, N; Itoh, M; Kanayama, H; Katada, N; Kato, T; Oda, N; Sawai, Y; Suzuki, A; Taguchi, H; Taki, F; Terabayashi, T; Yamada, K; Yamazaki, Y, 2009) |
| "In this series of males with metabolic syndrome, treatment with metformin associated with healthy dietary modifications and a mild physical activity increment resulted in significant improvement of insulin sensitivity and increase in total and free testosterone levels, regardless of the presence of hypogonadism." | 9.14 | Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome. ( Caldas, AD; Casulari, LA; Domingues Casulari Motta, L; Lofrano-Porto, A, 2010) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "We concluded that metformin improved vascular endothelial reactivity in first-degree relatives with metabolic syndrome of type 2 diabetic patients, independently of its known antihyperglycemic effects." | 9.12 | Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. ( Bahia, LR; Bottino, D; Bouskela, E; de Aguiar, LG; Laflor, C; Sicuro, F; Villela, N; Wiernsperger, N, 2006) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "For patients with type 2 diabetes mellitus and metabolic syndrome, combined treatment with metformin and rosiglitazone or pioglitazone is safe and effective, However, the pioglitazone combination also reduced the plasma Lp(a) levels whereas the rosiglitazone combination did not." | 9.12 | Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006) |
| " The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome." | 9.12 | Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2007) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 9.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 9.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| "The aim of our investigation was to study the peculiarities of serum uric acid (UA) levels in patients with metabolic syndrome (MS) during 6 month therapy with metformin (MF), Rosiglitazone (RG) and their combination." | 9.12 | [Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy]. ( Javashvili, L; Kilasonia, L; Tananashvili, D; Tetradze, L; Virsaladze, D, 2007) |
| "To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution." | 9.11 | The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. ( Fowler, S; Goldberg, R; Haffner, S; Marcovina, S; Orchard, TJ; Ratner, R; Temprosa, M, 2005) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 9.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome." | 9.11 | Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005) |
| "Metformin improves both endothelial function and insulin resistance in patients with MS." | 9.11 | Metformin improves endothelial function in patients with metabolic syndrome. ( Cornoldi, A; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 9.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 9.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 8.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Metformin have been reported to counteract effectively antipsychotic-induced body weight gain and has been demonstrated to improve glycaemic control and promote a moderate weight loss in both diabetic and non-diabetic subjects." | 8.91 | A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. ( Agius, M; Jesus, C; Jesus, I, 2015) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies." | 8.82 | Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. ( Fernandes, AW; Lester, JW, 2005) |
| "Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied." | 8.12 | Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome. ( Chernikova, A; Dmitriev, A; Ermolenko, E; Galagudza, M; Gladyshev, N; Karonova, T; Kotyleva, M; Lavrenova, N; Minasian, S; Simanenkova, A; Suvorov, A; Timkina, N; Voropaeva, L, 2022) |
| "The current study was conducted to investigate the nephroprotective effects of vildagliptin-metformin combination in an experimental model of fructose/salt-induced metabolic syndrome (MetS)." | 8.12 | Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome. ( Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Sabry, D; Wahba, NS, 2022) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 8.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| "The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome." | 8.02 | Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. ( Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L, 2021) |
| "The current study aimed to investigate the molecular mechanisms of metformin and vitamin D3-induced nephroprotection in a metabolic syndrome (MetS) rat model, evaluating the capacity of vitamin D3 to potentiate metformin action." | 8.02 | Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition. ( Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Wahba, NS, 2021) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 7.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 7.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| " We aimed to examine and compare the effects of Stevia's hydroalcoholic extract with two dosages (200, 400 mg/kg) with those of metformin (100 mg/kg) on metabolic syndrome (MetS) indices of rats fed with a high-fat, high-sucrose diet (HFHS)." | 7.96 | A comparison of the effects of Stevia extract and metformin on metabolic syndrome indices in rats fed with a high-fat, high-sucrose diet. ( Amanat, S; Azarpira, N; Koohi-Hosseinabadi, O; Masoumi, SJ; Monabati, A; Nekooeian, AA; Ranjbar, T; Tanideh, N, 2020) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 7.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "The present investigation was designed to explore the effectiveness of pterostilbene (PT) on insulin resistance, metabolic syndrome and oxidative stress in fructose-fed insulin resistant rats." | 7.85 | Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats. ( Kosuru, R; Singh, S, 2017) |
| "Newly diagnosed patients with metabolic syndrome and to be started on Table Metformin 500mg twice a day were recruited for the study after obtaining written informed consent." | 7.85 | Effect of metformin on exercise capacity in metabolic syndrome. ( Chandrasekaran, I; Dkhar, SA; George, M; Gunaseelan, V; Kamalanathan, S; Paul, AA; Selvarajan, S; Thabah, MM, 2017) |
| "To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 7.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
| "In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period." | 7.83 | Clinical Inquiry: Which patients with metabolic syndrome benefit from metformin? ( Chi, J; Kelsberg, G; Safranek, S; Stover, L, 2016) |
| "To determine the effects of metformin therapy in children with metabolic syndrome (MS)." | 7.81 | Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. ( Ashraf, AP; Luong, DQ; Oster, R, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Despite the limitations of this observational study, diabetes patients with MS who were treated with metformin plus DPP-4 inhibitors had better compliance, greater metabolic control, and lower rates of hypoglycemia, causing lower costs for the Spanish national health system than patients receiving metformin plus other antidiabetes drugs." | 7.80 | Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. ( Navarro-Artieda, R; Sicras-Mainar, A, 2014) |
| "The aim of the study was to evaluate results of combined therapy of stable 2-3 FC angina of effort with metabolic syndrome including metformin." | 7.80 | [Results of combined therapy of stable 2-3 FC angina of effort with metabolic syndrome including metformin]. ( Dashdamirov, RL, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 7.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "To describe a case where pharmacist prescribing of metformin therapy resulted in unexplained vaginal bleeding in a patient later diagnosed with complex endometrial hyperplasia." | 7.79 | Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia. ( Houle, SK; Lyster, RL, 2013) |
| "Metformin treatment in the context of metabolic syndrome and myocardial ischemia dramatically upregulates the insulin signaling pathway in chronically ischemic myocardium, which is at the crossroads of known metabolic and survival benefits of metformin." | 7.79 | Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. ( Chu, LM; Elmadhun, NY; Lassaletta, AD; Sellke, FW, 2013) |
| " At the end of the feeding schedule, Dia group had insulin resistance along with increased blood glucose, triglyceride, uric acid and nitric oxide (NO) levels." | 7.78 | Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. ( Bagul, PK; Banerjee, SK; Bastia, T; Chakravarty, S; Madhusudana, K; Matapally, S; Middela, H; Padiya, R; Reddy, BR, 2012) |
| "To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism." | 7.78 | [Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism]. ( Kaĭdashev, IP; Kutsenko, LA; Lavrenko, AV; Mamontova, TV; Shlykova, OA, 2012) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 7.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 7.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 7.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "7%) stopped metformin therapy due to excessive anorexia." | 7.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up." | 7.74 | Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. ( Fu, JF; Hong, F; Liang, L; Wang, CL; Wang, XM; Zhao, ZY; Zou, CC, 2007) |
| "The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin." | 7.74 | Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. ( Cowan, PA; Harden, KA; Patton, SB; Velasquez-Mieyer, P, 2007) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 7.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| "Fifty-seven type 2 diabetic patients with metabolic syndrome and on insulin were assessed by a paired analysis before and 6 months after addition of metformin as combination therapy to evaluate the impact of the association on glycemic control, blood pressure, and lipid profile." | 7.73 | Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. ( Dib, SA; Guedes, OM; Mourão-Júnior, CA; Sá, JR, 2006) |
| "Metformin treatment was associated with a significant decrease in HOMA-IR." | 7.01 | Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial. ( Bettencourt, N; Braga, P; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite, S; Leite-Moreira, A; Sampaio, F; Santos-Ferreira, D; Vilela, E, 2021) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 6.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "Metformin was administered in the dose of 50 mg daily to the overweight and obese participants." | 6.78 | Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention. ( Erzen, DJ; Hozo, I; Radman, M; Tesanović, D; Tesanović, S, 2013) |
| "Metabolic syndrome has several comorbidities, which result in a high cardiometabolic risk." | 6.73 | Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. ( Asbún, J; Ceballos, G; Elisa, ZN; Emma, MN; Guzman, M; Hicks, J; Meaney, A; Meaney, E; Samaniego, V; Vela, A; Zempoalteca, JC, 2008) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 6.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 6.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world." | 5.91 | Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. ( Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F, 2023) |
| "Microvascular insulin resistance is present in metabolic syndrome and may contribute to increased cardiovascular disease risk and the impaired metabolic response to insulin observed." | 5.72 | Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome. ( Barrett, EJ; Hartline, L; Jahn, LA; Liu, Z, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 5.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Metformin is a well-known AMPK activator widely used for the treatment of metabolic syndrome, while the mechanism of AMPK activation remains unclear." | 5.72 | Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle. ( Chen, J; Cheng, J; Guan, F; Huang, X; Li, M; Li, Y; Lin, G; Liu, Y; Ma, X; Su, Z; Xie, J; Xu, L; Yu, Q, 2022) |
| "Oral metformin treatment was able to prevent trabecular osteocyte loss and the reduction in extracellular mineralization induced by FRD-induced MS." | 5.46 | Effects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment. ( Aguirre, JI; Cortizo, AM; Felice, JI; McCarthy, AD; Schurman, L; Sedlinsky, C, 2017) |
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 5.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 5.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "To evaluate the effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome that are in menopausal transition." | 5.34 | Effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome: A randomized placebo-controlled trial. ( Dangrat, C; Indhavivadhana, S; Jirattigalachote, A; Rattanachaiyanont, M; Techatraisak, K; Wongwananurak, T, 2020) |
| "We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome." | 5.34 | Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. ( Cha, BS; Choi, DS; Choi, KM; Chun, SW; Kim, DM; Kim, KJ; Kim, MK; Kim, SG; Lee, HW; Lim, S; Mok, JO; Park, KS; Seo, JA; Shon, HS; Yoon, KH, 2020) |
| "Metformin or vehicle was administered to rats daily for 1 week." | 5.32 | Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| "Metformin treatment (1000-2000 mg/day) over 6 months in pubertal children and/or adolescents with obesity and hyperinsulinism is associated with a reduction in body mass index (BMI) and the insulin resistance index (HOMA-IR)." | 5.30 | Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Dorado-Ceballos, E; Ibáñez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Mas-Parés, B; Osiniri, I; Prats-Puig, A; Xargay-Torrent, S, 2019) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 5.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "This three-arm, randomized, controlled study aimed to determine the differences in the effects of general advice (GA) on lifestyle change, intensive lifestyle modification programme (ILMP) and GA + metformin (GA + Met) in reducing the prevalence of full metabolic syndrome (MetS) in subjects with prediabetes; 294 Saudis with prediabetes (fasting glucose 5." | 5.27 | Effects of Different Dietary and Lifestyle Modification Therapies on Metabolic Syndrome in Prediabetic Arab Patients: A 12-Month Longitudinal Study. ( Al-Attas, OS; Al-Daghri, NM; Al-Saleh, Y; Alfawaz, HA; Aljohani, NJ; Alnaami, AM; Alokail, MS; Kumar, S; Wani, K, 2018) |
| "In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups." | 5.27 | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. ( Bodur, S; Dundar, O; Kanat-Pektas, M; Kinci, MF; Tutuncu, L, 2018) |
| "We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes." | 5.27 | Use of a Metabolic Syndrome Severity ( DeBoer, MD; Filipp, SL; Gurka, MJ, 2018) |
| "To determine the relationship between the serum fetuin and insulin resistance in Type 1 diabetes subjects and the effect of short-term Metformin therapy on this relationship." | 5.27 | Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics. ( Abdelsalam, MM; Ahmed, IZ; Eid, YM; Mahdy, MM; Mansour, HK; Sheriba, NA, 2018) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 5.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 5.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months." | 5.20 | Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. ( Cypess, AM; Fitch, KV; Grinspoon, SK; Petrow, E; Srinivasa, S; Torriani, M; Wei, J; Wong, K, 2015) |
| "This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT)." | 5.20 | Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. ( Chen, M; Chen, Y; Dai, Y; Li, Y; Wang, Y; Xie, H; Zhao, X, 2015) |
| "The present study tested the hypothesis that pretreatment with metformin decreases postprocedural myocardial injury and improves clinical outcomes in metabolic syndrome patients following percutaneous coronary intervention (PCI)." | 5.19 | Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. ( Li, J; Song, SJ; Sun, XJ; Xu, JP; Xu, ZW; Zhao, XZ, 2014) |
| "This pilot study included 16 EAH patients who met at least one metabolic syndrome (MS) criterion and received either adjunctive metformin plus MA (MET group) or MA monotherapy (MA group)." | 5.19 | Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. ( Chen, X; Gu, C; Luo, X; Ning, C; Shan, W; Wang, C; Zhang, Z; Zhou, Q, 2014) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 5.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia." | 5.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "To investigate the effects of metformin and lifestyle changes on the development of androgen deprivation therapy (ADT)-related metabolic syndrome." | 5.16 | A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. ( Klopper, T; Laing, RW; Langley, SE; Nobes, JP; Russell-Jones, D, 2012) |
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 5.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "In a subanalysis on the metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome (MEFISTO)(8) (an open-label fashion, with 1 year of 850 mg daily of metformin) subjects' samples, we measured the paraoxonase 1 (PON1) activity in 39 patients that finished the study and relate values with high density lipoprotein (HDL)." | 5.16 | Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study. ( Ceballos, G; Guzmán-Grenfell, M; Hicks, JJ; Meaney, A; Meaney, E; Olivares-Corichi, I; Ramírez-Sánchez, I; Sierra-Vargas, P, 2012) |
| "To examine the appropriate treatment of oligo-terato-asthenozoospermic patients with metabolic syndrome, 45 patients were treated with metformin for 6 months." | 5.15 | Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome. ( De Leo, V; Morgante, G; Musacchio, MC; Orvieto, R; Piomboni, P; Tosti, C, 2011) |
| "To test whether a portion control diet could prevent weight gain during treatment with pioglitazone in patients with type 2 diabetes mellitus (T2DM)." | 5.14 | Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. ( Bray, GA; Greenway, FL; Gupta, AK; Smith, SR, 2009) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen." | 5.14 | Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen ( Bouskela, E; Kraemer-Aguiar, LG; Lima, LM; Wiernsperger, N, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin." | 5.14 | Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. ( Baccara-Dinet, M; Charles, MA; Diouf, I; Eschwege, E; Fontbonne, A, 2009) |
| "The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome." | 5.14 | Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. ( Hayakawa, N; Itoh, M; Kanayama, H; Katada, N; Kato, T; Oda, N; Sawai, Y; Suzuki, A; Taguchi, H; Taki, F; Terabayashi, T; Yamada, K; Yamazaki, Y, 2009) |
| "In this series of males with metabolic syndrome, treatment with metformin associated with healthy dietary modifications and a mild physical activity increment resulted in significant improvement of insulin sensitivity and increase in total and free testosterone levels, regardless of the presence of hypogonadism." | 5.14 | Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome. ( Caldas, AD; Casulari, LA; Domingues Casulari Motta, L; Lofrano-Porto, A, 2010) |
| "The second generation antipsychotic drugs, such as risperidone, olanzapine, and quetiapine, are effective in treating patients with schizophrenia and have been considered as the first line therapy." | 5.13 | Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. ( Chen, CH; Chiu, CC; Huang, MC; Liu, HC; Lu, ML; Wu, TH, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| " An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course." | 5.12 | Metabolic Disorders in Multiple Myeloma. ( Dimopoulos, MA; Gavriatopoulou, M; Ntanasis-Stathopoulos, I; Paschou, SA, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "We concluded that metformin improved vascular endothelial reactivity in first-degree relatives with metabolic syndrome of type 2 diabetic patients, independently of its known antihyperglycemic effects." | 5.12 | Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. ( Bahia, LR; Bottino, D; Bouskela, E; de Aguiar, LG; Laflor, C; Sicuro, F; Villela, N; Wiernsperger, N, 2006) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "For patients with type 2 diabetes mellitus and metabolic syndrome, combined treatment with metformin and rosiglitazone or pioglitazone is safe and effective, However, the pioglitazone combination also reduced the plasma Lp(a) levels whereas the rosiglitazone combination did not." | 5.12 | Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006) |
| " The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome." | 5.12 | Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2007) |
| "In this study, the Authors assessed some insulin counter-regulatory factors, fibrinogen and C-reactive protein after olanzapine administration, and the effect of metformin on these variables, 37 patients with chronic schizophrenia were given olanzapine (10 mg/day for 14 weeks)." | 5.12 | Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. ( Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D, 2007) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 5.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 5.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| "The aim of our investigation was to study the peculiarities of serum uric acid (UA) levels in patients with metabolic syndrome (MS) during 6 month therapy with metformin (MF), Rosiglitazone (RG) and their combination." | 5.12 | [Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy]. ( Javashvili, L; Kilasonia, L; Tananashvili, D; Tetradze, L; Virsaladze, D, 2007) |
| "To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution." | 5.11 | The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. ( Fowler, S; Goldberg, R; Haffner, S; Marcovina, S; Orchard, TJ; Ratner, R; Temprosa, M, 2005) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 5.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome." | 5.11 | Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005) |
| "Metformin improves both endothelial function and insulin resistance in patients with MS." | 5.11 | Metformin improves endothelial function in patients with metabolic syndrome. ( Cornoldi, A; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 5.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 5.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| " Metformin seems to be safe and presents evident positive effects on insulin sensitivity, but long-term and consistent data are still missing to establish its role in the pediatric population and the possible effectiveness of other emergent treatments such as glucagon-like peptide-1 analogues, dipeptidylpeptidase-4 inhibitors, dual inhibitors of SGLT1 and SGLT2 and weight loss drugs." | 5.05 | Metabolic syndrome in children. ( Chiarelli, F; Samvelyan, S; Tagi, VM, 2020) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 4.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Metformin have been reported to counteract effectively antipsychotic-induced body weight gain and has been demonstrated to improve glycaemic control and promote a moderate weight loss in both diabetic and non-diabetic subjects." | 4.91 | A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. ( Agius, M; Jesus, C; Jesus, I, 2015) |
| "A MEDLINE, Pubmed and Cochrane Review database search using a combination of keywords, which included non-alcoholic fatty liver disease, non-alcoholic hepatic steatosis, NAFLD, NASH, treatment, therapeutics, vitamin E, orlistat and bariatric surgery." | 4.90 | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. ( Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM, 2014) |
| " Treatment with metformin has been shown to improve insulin sensitivity, lowering blood glucose and androgen levels." | 4.90 | Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. ( Spritzer, PM, 2014) |
| "Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
| "A literature review using PubMed with the keywords: AMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken." | 4.87 | Metformin in prostate cancer: two for the price of one. ( Ali, SS; Clements, A; Gao, B; Gurney, H; Wong, MKY; Yeap, SHO, 2011) |
| " In at least two randomized controlled studies, metformin proved to be clinically effective in increasing insulin sensitivity in hyperinsulinemic, nondiabetic adolescents." | 4.82 | Insulin resistance syndrome in children : pathophysiology and potential management strategies. ( Decsi, T; Molnár, D, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| " Search terms used were insulin resistance, diabetes, insulin sensitivity, obesity, cardiovascular disease, metformin, thiazolidinediones, pioglitazone, rosiglitazone, and troglitazone." | 4.82 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. ( Henry, RR, 2003) |
| "Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies." | 4.82 | Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. ( Fernandes, AW; Lester, JW, 2005) |
| " Metabolic syndrome and polycystic ovary syndrome diagnosed patients with insulin resistance and/or impaired glucose tolerance, patients with type 2 diabetes mellitus (DM) treated with metformin were enrolled in study." | 4.12 | Does Metformin Treatment in Pediatric Population Cause Vitamin B12 Deficiency? ( Berberoglu, M; Dogan, O; Eminoglu, FT; Kontbay, T; Kose, E; Siklar, Z; Taş, Ö; Tumer, L, 2022) |
| "The main aim was to study whether the long-term incidences of type 2 diabetes, pre-diabetes and metabolic syndrome differed between women who were treated with metformin or insulin for gestational diabetes." | 4.12 | Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials. ( Huhtala, M; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Rönnemaa, T; Tertti, K; Vääräsmäki, M, 2022) |
| "Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied." | 4.12 | Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome. ( Chernikova, A; Dmitriev, A; Ermolenko, E; Galagudza, M; Gladyshev, N; Karonova, T; Kotyleva, M; Lavrenova, N; Minasian, S; Simanenkova, A; Suvorov, A; Timkina, N; Voropaeva, L, 2022) |
| " Ten adult patients (26-61 years) with prolactinomas (7 M), persistent hyperprolactinemia (38-386 ng/mL) under cabergoline treatment (2-7 mg/week) for at least 6 months (6-108 months), features of metabolic syndrome, and not taking metformin were included." | 4.12 | Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study. ( Abucham, J; Correa-Silva, SR; Portari, LHC, 2022) |
| "The current study was conducted to investigate the nephroprotective effects of vildagliptin-metformin combination in an experimental model of fructose/salt-induced metabolic syndrome (MetS)." | 4.12 | Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome. ( Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Sabry, D; Wahba, NS, 2022) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 4.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| " We evaluated the role of oxidative stress (OS), during early metabolic syndrome (MetS), on amyloidogenic processes in a MetS rat model induced by sucrose." | 4.02 | Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation. ( Baires-López, A; Camacho-Castillo, L; Campos-Peña, V; Carvajal, K; Phillips-Farfán, BV; Rosas-Mendoza, G; Toral-Ríos, D, 2021) |
| "The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome." | 4.02 | Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. ( Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L, 2021) |
| "The current study aimed to investigate the molecular mechanisms of metformin and vitamin D3-induced nephroprotection in a metabolic syndrome (MetS) rat model, evaluating the capacity of vitamin D3 to potentiate metformin action." | 4.02 | Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition. ( Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Wahba, NS, 2021) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 3.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 3.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| " We aimed to examine and compare the effects of Stevia's hydroalcoholic extract with two dosages (200, 400 mg/kg) with those of metformin (100 mg/kg) on metabolic syndrome (MetS) indices of rats fed with a high-fat, high-sucrose diet (HFHS)." | 3.96 | A comparison of the effects of Stevia extract and metformin on metabolic syndrome indices in rats fed with a high-fat, high-sucrose diet. ( Amanat, S; Azarpira, N; Koohi-Hosseinabadi, O; Masoumi, SJ; Monabati, A; Nekooeian, AA; Ranjbar, T; Tanideh, N, 2020) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 3.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "This paper describes a novel software created specifically for the management of a randomized trial of diet and metformin in people with metabolic syndrome (the Me." | 3.91 | A management system for randomized clinical trials: A novel way to supply medication. ( Baldassari, I; Berrino, F; Bruno, E; Casagrande, A; Cortellini, M; Del Sette, D; Di Mauro, MG; Fornaciari, G; Gargano, G; Oliverio, A; Pasanisi, P; Saibene, G; Venturelli, E; Villarini, A, 2019) |
| "Metformin decreased glucose concentrations, reduced metabolic syndrome, as well as insulin dose requirement more than insulin therapy alone, 1 year after treatment." | 3.88 | The effects of metformin in type 1 diabetes mellitus. ( Beysel, S; Cakal, E; Caliskan, M; Kizilgul, M; Ucan, B; Unsal, IO, 2018) |
| "The present investigation was designed to explore the effectiveness of pterostilbene (PT) on insulin resistance, metabolic syndrome and oxidative stress in fructose-fed insulin resistant rats." | 3.85 | Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats. ( Kosuru, R; Singh, S, 2017) |
| "Newly diagnosed patients with metabolic syndrome and to be started on Table Metformin 500mg twice a day were recruited for the study after obtaining written informed consent." | 3.85 | Effect of metformin on exercise capacity in metabolic syndrome. ( Chandrasekaran, I; Dkhar, SA; George, M; Gunaseelan, V; Kamalanathan, S; Paul, AA; Selvarajan, S; Thabah, MM, 2017) |
| "To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 3.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
| "Metformin, a biguanide drug, is emerging as an important treatment option for the prevention or treatment of weight gain, type 2 diabetes mellitus, and the metabolic syndrome in psychiatric patients, especially those who require or receive antipsychotic drugs." | 3.83 | Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues. ( Andrade, C, 2016) |
| "In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period." | 3.83 | Clinical Inquiry: Which patients with metabolic syndrome benefit from metformin? ( Chi, J; Kelsberg, G; Safranek, S; Stover, L, 2016) |
| "To determine the effects of metformin therapy in children with metabolic syndrome (MS)." | 3.81 | Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. ( Ashraf, AP; Luong, DQ; Oster, R, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Metformin and phosphatidylcholine attenuated lipopolysaccharide induced toll-like receptor 4 overexpression and overproduction of pro-inflammatory cytokines; however, their efficacy depended on combined presence of non-alcoholic fatty liver disease, metabolic syndrome and obesity." | 3.81 | Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate. ( Daniluk, J; Kandefer-Szerszeń, M; Szuster-Ciesielska, A; Słabczyńska, O; Zwolak, A, 2015) |
| "Despite the limitations of this observational study, diabetes patients with MS who were treated with metformin plus DPP-4 inhibitors had better compliance, greater metabolic control, and lower rates of hypoglycemia, causing lower costs for the Spanish national health system than patients receiving metformin plus other antidiabetes drugs." | 3.80 | Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. ( Navarro-Artieda, R; Sicras-Mainar, A, 2014) |
| " Peripheral insulin resistance was also enhanced and the GP in charge decided to discontinue the dosing of metformin as a result." | 3.80 | [Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle]. ( Alegre, A; Ferri, A; Martinez, MI; Mateos, AM, 2014) |
| "The aim of the study was to evaluate results of combined therapy of stable 2-3 FC angina of effort with metabolic syndrome including metformin." | 3.80 | [Results of combined therapy of stable 2-3 FC angina of effort with metabolic syndrome including metformin]. ( Dashdamirov, RL, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 3.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "To describe a case where pharmacist prescribing of metformin therapy resulted in unexplained vaginal bleeding in a patient later diagnosed with complex endometrial hyperplasia." | 3.79 | Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia. ( Houle, SK; Lyster, RL, 2013) |
| "Metformin treatment in the context of metabolic syndrome and myocardial ischemia dramatically upregulates the insulin signaling pathway in chronically ischemic myocardium, which is at the crossroads of known metabolic and survival benefits of metformin." | 3.79 | Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. ( Chu, LM; Elmadhun, NY; Lassaletta, AD; Sellke, FW, 2013) |
| "Metformin is a hypoglycaemic drug currently used to increase insulin sensitivity in the treatment of type 2 diabetes and metabolic syndrome." | 3.78 | Metformin reduces vascular production of vasoconstrictor prostanoids in fructose overloaded rats. ( Borroni, JS; Boudou, S; Carranza, A; Donoso, AS; Peredo, HA; Puyó, AM; Santander, Y, 2012) |
| " At the end of the feeding schedule, Dia group had insulin resistance along with increased blood glucose, triglyceride, uric acid and nitric oxide (NO) levels." | 3.78 | Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. ( Bagul, PK; Banerjee, SK; Bastia, T; Chakravarty, S; Madhusudana, K; Matapally, S; Middela, H; Padiya, R; Reddy, BR, 2012) |
| "To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism." | 3.78 | [Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism]. ( Kaĭdashev, IP; Kutsenko, LA; Lavrenko, AV; Mamontova, TV; Shlykova, OA, 2012) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 3.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 3.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "To make available experimental model for the metabolic syndrome (MS) and verify effects of chronic oral treatment with metformin upon blood pressure (BP), body weight (BW), glucose metabolism, epididimal fat content (EF)." | 3.75 | [Metformin effects upon blood pressure and glucose metabolism of monossodium glutamate induced-obese spontaneously hypertensive rats]. ( Cesaretti, ML; Ferreira, CB; Ginoza, M; Kohlmann, O, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 3.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "7%) stopped metformin therapy due to excessive anorexia." | 3.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up." | 3.74 | Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. ( Fu, JF; Hong, F; Liang, L; Wang, CL; Wang, XM; Zhao, ZY; Zou, CC, 2007) |
| "The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin." | 3.74 | Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. ( Cowan, PA; Harden, KA; Patton, SB; Velasquez-Mieyer, P, 2007) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 3.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| "Fifty-seven type 2 diabetic patients with metabolic syndrome and on insulin were assessed by a paired analysis before and 6 months after addition of metformin as combination therapy to evaluate the impact of the association on glycemic control, blood pressure, and lipid profile." | 3.73 | Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. ( Dib, SA; Guedes, OM; Mourão-Júnior, CA; Sá, JR, 2006) |
| " This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS." | 3.01 | Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. ( Cui, L; Qian, H; Tang, M; Wang, J; Wang, L; Wang, R; Wei, M; Xu, W, 2021) |
| "Metformin treatment was associated with a significant decrease in HOMA-IR." | 3.01 | Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial. ( Bettencourt, N; Braga, P; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite, S; Leite-Moreira, A; Sampaio, F; Santos-Ferreira, D; Vilela, E, 2021) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 2.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "Metformin was administered in the dose of 50 mg daily to the overweight and obese participants." | 2.78 | Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention. ( Erzen, DJ; Hozo, I; Radman, M; Tesanović, D; Tesanović, S, 2013) |
| "Metabolic syndrome has several comorbidities, which result in a high cardiometabolic risk." | 2.73 | Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. ( Asbún, J; Ceballos, G; Elisa, ZN; Emma, MN; Guzman, M; Hicks, J; Meaney, A; Meaney, E; Samaniego, V; Vela, A; Zempoalteca, JC, 2008) |
| "Metformin is a widely used glucose-lowering drug, although its impact on adipose tissue function remains elusive." | 2.72 | Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials. ( Cirilli, I; Dludla, PV; Louw, J; Marcheggiani, F; Mazibuko-Mbeje, SE; Mokgalaboni, K; Mxinwa, V; Nkambule, BB; Nyambuya, TM; Tiano, L; Ziqubu, K, 2021) |
| "Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles." | 2.72 | Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. ( Driver, C; Gcwensa, SK; Mbara, KC; Mcobothi, EN; Mkhombo, NT; Mofo Mato, PE; Nzuza, S; Owira, PM, 2021) |
| "Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC." | 2.72 | A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. ( Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years." | 2.58 | Metformin: An Old Drug with New Applications. ( Li, L; Massey, S; Story, D; Zhou, J, 2018) |
| "The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI." | 2.55 | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017) |
| "Metformin remains the cure for the treatment of insulin resistance." | 2.55 | [The Role of Reactive Oxygen Species in the Pathogenesis of Adipocyte Dysfunction in Metabolic Syndrome. Prospects of Pharmacological Correction]. ( Bespalova, ID; Ivanov, VV; Maslov, LN; Pismennyi, DS; Prokudina, ES; Voronkov, NS, 2017) |
| "Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)." | 2.53 | Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016) |
| "Patients with schizophrenia have increased prevalence rates for many cardiometabolic risk factors; the prevalence and severity of these risks increase after the institution of antipsychotic medication." | 2.53 | Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions. ( Andrade, C, 2016) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 2.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "Insulin resistance is prevalent in women with polycystic ovary syndrome (PCOS), and plays a critical pathophysiologic role in both the metabolic and reproductive complications of PCOS." | 2.52 | Polycystic ovary syndrome and insulin: our understanding in the past, present and future. ( Evans, WS; Mayer, SB; Nestler, JE, 2015) |
| "Chemoprevention in Barrett's esophagus is currently applied only in research settings." | 2.52 | Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)." | 2.52 | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015) |
| "Metabolic syndrome is a cluster of conditions that synergistically increase the risk of cardiovascular disease, type 2 diabetes, and premature mortality." | 2.52 | Metabolic Syndrome: Insulin Resistance and Prediabetes. ( Mayans, L, 2015) |
| "Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors." | 2.49 | Metabolic syndrome as a peculiar target for management of prostate cancer patients. ( Aieta, M; Ardito, R; Bozza, G; Conteduca, V; Di Lorenzo, G, 2013) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide." | 2.49 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013) |
| "The metabolic syndrome affects 30% of the US population with increasing prevalence." | 2.48 | The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. ( Hutcheson, R; Rocic, P, 2012) |
| "Over 2." | 2.48 | Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. ( Goldberg, RB; Mather, K, 2012) |
| "Metabolic syndrome is prevalent in older adults and increases the risk of cardiovascular disease." | 2.45 | Metabolic risks in older adults receiving second-generation antipsychotic medication. ( Brooks, JO; Chang, HS; Krasnykh, O, 2009) |
| "Metabolic syndrome is a chronic low-grade inflammatory condition in which adipokines play a major role." | 2.45 | Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. ( Damato, AB; Depalo, R; Garruti, G; Giampetruzzi, F; Giorgino, F; Lorusso, F; Vita, MG, 2009) |
| "Treatment of type 2 diabetes (T2DM) is based on lifestyle changes and oral antidiabetic agents or insulin." | 2.44 | [New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. ( Debaty, I; Halimi, S; Muller, M; Villaret, L, 2008) |
| "Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America." | 2.44 | Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007) |
| "The recommended first step for treatment of metabolic syndrome is lifestyle modifications such as weight loss, aerobic exercise, smoking cessation, and improved diet which independently improve insulin resistance and slow progression to type 2 diabetes mellitus." | 2.44 | Metabolic syndrome: are we at risk? ( Paudel, B, 2007) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 2.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Metformin effectiveness has been shown for the reduction of diabetes related complications and mortality, mainly in the cardiovascular field." | 2.42 | [Metabolic syndrome: to observe or to act?]. ( Picard, S; Slama, G, 2003) |
| "The predicted global epidemic of type 2 diabetes highlights the importance of identifying the most effective ways to reduce the risk of long-term diabetic complications." | 2.42 | Metformin and vascular protection: a cardiologist's view. ( Libby, P, 2003) |
| "The public health burden of type 2 diabetes mellitus has been dramatically increased worldwide." | 2.42 | [Is type-2 diabetes mellitus preventable?]. ( Jermendy, G, 2003) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.42 | Current indications for metformin therapy. ( Tankova, T, 2003) |
| "Treatment with metformin allows to decrease insulin resistance and thus severity of derangements of metabolism." | 2.41 | [Metabolic syndrome from the point of view of a cardiologist: diagnosis, non drug and drug treatment]. ( Makolkin, VI; Napalkov, DA; Podzolkov, VI, 2002) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world." | 1.91 | Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. ( Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F, 2023) |
| "Microvascular insulin resistance is present in metabolic syndrome and may contribute to increased cardiovascular disease risk and the impaired metabolic response to insulin observed." | 1.72 | Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome. ( Barrett, EJ; Hartline, L; Jahn, LA; Liu, Z, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis." | 1.72 | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 1.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Metformin is a well-known AMPK activator widely used for the treatment of metabolic syndrome, while the mechanism of AMPK activation remains unclear." | 1.72 | Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle. ( Chen, J; Cheng, J; Guan, F; Huang, X; Li, M; Li, Y; Lin, G; Liu, Y; Ma, X; Su, Z; Xie, J; Xu, L; Yu, Q, 2022) |
| "Metformin treatment of the diabetic/obese mice effectively normalized glucose levels, reconfigured the mammary tumor milieu, and decreased metastatic seeding." | 1.62 | Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. ( Alsheikh, HAM; Ha, CM; Hinshaw, DC; Kammerud, SC; Lama-Sherpa, T; Metge, BJ; Mota, MSV; Samant, RS; Sharafeldin, N; Shevde, LA; Wende, AR, 2021) |
| "Metformin intervention was used to further evaluate potential therapeutic amelioration of cardiac dysfunction in this model." | 1.51 | Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease. ( Archer, SK; Bais, P; Cagnone, G; Chandran, A; Coleman, D; Costa, MW; Forte, E; Furtado, MB; Heineke, J; Hon, O; Kocalis, H; Pandey, R; Patel, HH; Pearson, JT; Philip, V; Ramialison, M; Rosenthal, NA; Schilling, JM; Wilmanns, JC; Wu, Q, 2019) |
| "Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease." | 1.48 | Inflammatory signatures distinguish metabolic health in African American women with obesity. ( Andrieu, G; Bertrand, KA; Denis, GV; Medina, ND; Palmer, JR; Sebastiani, P; Slama, J; Strissel, KJ; Tran, AH, 2018) |
| "HFD successfully induces gallstone (4 out of 4 of the HFD members)." | 1.48 | Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice. ( Dehghanian, A; Dorvash, MR; Firouzabadi, N; Khoshnood, MJ; Mosaddeghi, P; Saber, H, 2018) |
| "Metformin treatment increased the number of structural defects of the myelin sheet surrounding these fibers in already affected nerves of HFD fed mice, and simvastatin treatment reduced these numbers to the levels seen in control mice." | 1.48 | Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice. ( Bumbasirevic, V; Ciric, D; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V, 2018) |
| "Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause." | 1.46 | Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| "Oral metformin treatment was able to prevent trabecular osteocyte loss and the reduction in extracellular mineralization induced by FRD-induced MS." | 1.46 | Effects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment. ( Aguirre, JI; Cortizo, AM; Felice, JI; McCarthy, AD; Schurman, L; Sedlinsky, C, 2017) |
| "Metabolic syndrome has been associated with nodular goiter." | 1.42 | Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome. ( Barreto, A; Blanc, E; Brenta, G; Brodschi, D; Cejas, C; Faingold, C; Fossati, P; Musso, C; Nepote, A; Ponce, C; Salgado, P; Schnitman, M, 2015) |
| "Treatment with metformin was associated with a significant weight reduction (P = 0·033), which resulted from a decrease in BF% (P = 0·044) but was not associated with changes in android and gynoid depots." | 1.40 | Changes in adiponectin level and fat distribution in patients with type 2 diabetes. ( Dziwura-Ogonowska, J; Iskierska, K; Miazgowski, T; Safranow, K; Widecka, K, 2014) |
| "Metformin has been shown to be effective therapy and could be used more widely in obese adolescents with hyperandrogenemia, a forerunner of PCOS." | 1.38 | Should all women with PCOS be treated for insulin resistance? ( Dunaif, A; Marshall, JC, 2012) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Obesity is a common problem and its health consequences depend on the phenotype of obesity." | 1.38 | Menopausal obesity and metabolic syndrome - PolSenior study. ( Milewicz, A, 2012) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 1.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "Micro vascular morphology and hemodynamics were evaluated non-invasively by means of nailfold videocapillaroscopy." | 1.34 | [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions]. ( Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR, 2007) |
| "The metabolic syndrome was present in 64 (46%) of the women with PCOS." | 1.32 | Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. ( Glueck, CJ; Goldenberg, N; Papanna, R; Sieve-Smith, L; Wang, P, 2003) |
| "Impaired glucose tolerance is defined as two-hour glucose levels of 140 to 199 mg per dL (7." | 1.32 | Impaired glucose tolerance and impaired fasting glucose. ( Disraeli, P; McGregor, T; Rao, SS, 2004) |
| "Metformin or vehicle was administered to rats daily for 1 week." | 1.32 | Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 97 (35.02) | 29.6817 |
| 2010's | 135 (48.74) | 24.3611 |
| 2020's | 45 (16.25) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Xiao, L | 1 |
| Li, S | 2 |
| Camacho-Castillo, L | 1 |
| Phillips-Farfán, BV | 1 |
| Rosas-Mendoza, G | 1 |
| Baires-López, A | 1 |
| Toral-Ríos, D | 1 |
| Campos-Peña, V | 1 |
| Carvajal, K | 1 |
| Qian, H | 1 |
| Xu, W | 1 |
| Cui, L | 1 |
| Wang, R | 1 |
| Wang, J | 3 |
| Tang, M | 1 |
| Wei, M | 1 |
| Wang, L | 2 |
| Gavriatopoulou, M | 1 |
| Paschou, SA | 1 |
| Ntanasis-Stathopoulos, I | 1 |
| Dimopoulos, MA | 1 |
| Cheng, L | 1 |
| Fu, Q | 1 |
| Zhou, L | 1 |
| Fan, Y | 2 |
| Liu, F | 1 |
| Zhang, X | 3 |
| Lin, W | 1 |
| Wu, X | 2 |
| Seikrit, C | 1 |
| Lausberg, E | 1 |
| Buhl, EM | 1 |
| Gaspar, R | 2 |
| Tabi, T | 2 |
| Heffer, M | 2 |
| Ducza, E | 2 |
| Sztojkov-Ivanov, A | 2 |
| Seres, AB | 1 |
| Szucs, K | 1 |
| Ivic, V | 2 |
| Floege, J | 1 |
| Vari, SG | 2 |
| Boor, P | 1 |
| Klinkhammer, BM | 1 |
| Jahn, LA | 1 |
| Hartline, L | 1 |
| Liu, Z | 1 |
| Barrett, EJ | 1 |
| Taş, Ö | 1 |
| Kontbay, T | 1 |
| Dogan, O | 1 |
| Kose, E | 1 |
| Berberoglu, M | 1 |
| Siklar, Z | 1 |
| Tumer, L | 1 |
| Eminoglu, FT | 1 |
| Huhtala, M | 1 |
| Nikkinen, H | 1 |
| Paavilainen, E | 1 |
| Niinikoski, H | 1 |
| Vääräsmäki, M | 1 |
| Loo, BM | 1 |
| Rönnemaa, T | 1 |
| Tertti, K | 1 |
| Zhou, ST | 1 |
| Cui, W | 1 |
| Kong, L | 1 |
| Yang, X | 3 |
| Tian, R | 1 |
| Hong, J | 1 |
| Zhao, J | 1 |
| Zhou, D | 1 |
| Liu, Y | 2 |
| Jiao, Z | 1 |
| Song, J | 2 |
| Zhang, Y | 4 |
| Meng, L | 1 |
| Yu, M | 1 |
| Ermolenko, E | 1 |
| Simanenkova, A | 1 |
| Voropaeva, L | 1 |
| Lavrenova, N | 1 |
| Kotyleva, M | 1 |
| Minasian, S | 1 |
| Chernikova, A | 1 |
| Timkina, N | 1 |
| Gladyshev, N | 1 |
| Dmitriev, A | 1 |
| Suvorov, A | 1 |
| Galagudza, M | 1 |
| Karonova, T | 1 |
| Gradisteanu Pircalabioru, G | 1 |
| Liaw, J | 1 |
| Gundogdu, O | 1 |
| Corcionivoschi, N | 1 |
| Ilie, I | 1 |
| Oprea, L | 1 |
| Musat, M | 1 |
| Chifiriuc, MC | 1 |
| Reifsnyder, PC | 1 |
| Flurkey, K | 1 |
| Doty, R | 1 |
| Calcutt, NA | 1 |
| Koza, RA | 1 |
| Harrison, DE | 1 |
| Cheng, J | 1 |
| Xu, L | 2 |
| Yu, Q | 1 |
| Lin, G | 1 |
| Ma, X | 1 |
| Li, M | 1 |
| Guan, F | 1 |
| Huang, X | 1 |
| Xie, J | 1 |
| Chen, J | 1 |
| Su, Z | 1 |
| Li, Y | 6 |
| Eleazu, CO | 1 |
| Obeten, UN | 1 |
| Ozor, G | 1 |
| Njemanze, CC | 1 |
| Eleazu, KC | 1 |
| Egedigwe-Ekeleme, AC | 1 |
| Okorie, UC | 1 |
| Ogunwa, SC | 1 |
| Adeolu, AI | 1 |
| Okoh, PN | 1 |
| Kalu, AO | 1 |
| Onyia, CJ | 1 |
| Onyia, S | 1 |
| Ossai, P | 1 |
| Chikezie, CC | 1 |
| Odii, BC | 1 |
| Obi, V | 1 |
| Igwe, VM | 1 |
| Amobi, CA | 1 |
| Ugada, OJ | 1 |
| Kalu, WO | 1 |
| Kanu, S | 1 |
| Augusto, CT | 1 |
| de la Paz Scribano Parada, M | 1 |
| Rossi, MM | 1 |
| Signorini, F | 1 |
| Fonseca, I | 1 |
| Del Carmen Baez, M | 1 |
| Korbonits, M | 1 |
| Hambly, R | 1 |
| Kearney, N | 1 |
| Hughes, R | 1 |
| Fletcher, JM | 1 |
| Kirby, B | 1 |
| Mahalingam, D | 1 |
| Hanni, S | 1 |
| Serritella, AV | 1 |
| Fountzilas, C | 1 |
| Michalek, J | 1 |
| Hernandez, B | 1 |
| Sarantopoulos, J | 1 |
| Datta, P | 1 |
| Romero, O | 1 |
| Pillai, SMA | 1 |
| Kuhn, J | 1 |
| Pollak, M | 1 |
| Thompson, IM | 1 |
| Zjalić, M | 1 |
| Blažetić, S | 1 |
| Fenrich, M | 1 |
| Labak, I | 1 |
| Scitovski, R | 1 |
| Szűcs, KF | 1 |
| Bagamery, F | 1 |
| Szökő, É | 1 |
| Vuković, R | 1 |
| Rončević, A | 1 |
| Mandić, D | 1 |
| Debeljak, Ž | 1 |
| Berecki, M | 1 |
| Balog, M | 1 |
| Seres-Bokor, A | 1 |
| Hajagos-Tóth, J | 1 |
| Gajović, S | 1 |
| Imširović, A | 1 |
| Bakula, M | 1 |
| Mahiiovych, S | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 3 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, L | 5 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 7 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 5 |
| Hu, X | 1 |
| Li, Z | 2 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, J | 3 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 2 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Geng, Y | 1 |
| Wang, X | 2 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 2 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 2 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 3 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 2 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 2 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 2 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 3 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 2 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 2 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Adeshirlarijaney, A | 1 |
| Zou, J | 1 |
| Tran, HQ | 1 |
| Chassaing, B | 1 |
| Gewirtz, AT | 1 |
| Merino, J | 1 |
| Jablonski, KA | 1 |
| Mercader, JM | 1 |
| Kahn, SE | 2 |
| Chen, L | 1 |
| Harden, M | 1 |
| Delahanty, LM | 1 |
| Araneta, MRG | 1 |
| Walford, GA | 1 |
| Jacobs, SBR | 1 |
| Ibebuogu, UN | 1 |
| Franks, PW | 1 |
| Knowler, WC | 1 |
| Florez, JC | 1 |
| Pelusi, C | 1 |
| Fanelli, F | 1 |
| Baccini, M | 1 |
| Triggiani, V | 1 |
| Bartolomeo, N | 1 |
| Carbone, MD | 1 |
| De Pergola, G | 1 |
| Di Dalmazi, G | 1 |
| Pagotto, U | 2 |
| Pasquali, R | 3 |
| Giagulli, VA | 1 |
| Bassols, J | 1 |
| Martínez-Calcerrada, JM | 1 |
| Osiniri, I | 1 |
| Díaz-Roldán, F | 1 |
| Xargay-Torrent, S | 1 |
| Mas-Parés, B | 1 |
| Dorado-Ceballos, E | 1 |
| Prats-Puig, A | 1 |
| Carreras-Badosa, G | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| López-Bermejo, A | 1 |
| Muñoz-Arenas, G | 2 |
| Pulido, G | 1 |
| Treviño, S | 2 |
| Vázquez-Roque, R | 2 |
| Flores, G | 2 |
| Moran, C | 1 |
| Handal-Silva, A | 1 |
| Guevara, J | 2 |
| Venegas, B | 2 |
| Díaz, A | 2 |
| Halliday, G | 1 |
| Huot, JR | 1 |
| Satoh, T | 1 |
| Baust, JJ | 1 |
| Fisher, A | 1 |
| Cook, T | 1 |
| Hu, J | 1 |
| Avolio, T | 1 |
| Goncharov, DA | 1 |
| Bai, Y | 1 |
| Vanderpool, RR | 1 |
| Considine, RV | 1 |
| Bonetto, A | 1 |
| Tan, J | 1 |
| Bachman, TN | 1 |
| Sebastiani, A | 1 |
| McTiernan, CF | 1 |
| Mora, AL | 1 |
| Machado, RF | 1 |
| Goncharova, EA | 1 |
| Gladwin, MT | 1 |
| Lai, YC | 1 |
| Tagi, VM | 1 |
| Samvelyan, S | 1 |
| Chiarelli, F | 2 |
| Kim, EK | 1 |
| Min, HK | 1 |
| Lee, SY | 1 |
| Kim, DS | 1 |
| Ryu, JG | 1 |
| Na, HS | 1 |
| Jung, KA | 1 |
| Choi, JW | 1 |
| Park, SH | 1 |
| Cho, ML | 1 |
| Indhavivadhana, S | 1 |
| Rattanachaiyanont, M | 1 |
| Wongwananurak, T | 1 |
| Techatraisak, K | 1 |
| Jirattigalachote, A | 1 |
| Dangrat, C | 1 |
| Kim, SG | 1 |
| Kim, KJ | 1 |
| Yoon, KH | 1 |
| Chun, SW | 1 |
| Park, KS | 1 |
| Choi, KM | 1 |
| Lim, S | 2 |
| Mok, JO | 1 |
| Lee, HW | 1 |
| Seo, JA | 1 |
| Cha, BS | 1 |
| Kim, MK | 1 |
| Shon, HS | 1 |
| Choi, DS | 1 |
| Kim, DM | 1 |
| Ranjbar, T | 1 |
| Nekooeian, AA | 1 |
| Tanideh, N | 1 |
| Koohi-Hosseinabadi, O | 1 |
| Masoumi, SJ | 1 |
| Amanat, S | 1 |
| Azarpira, N | 1 |
| Monabati, A | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Goldenberg, R | 1 |
| Bell, A | 1 |
| Cheng, W | 1 |
| Fils-Aimé, N | 1 |
| Burrows, M | 1 |
| Blavignac, J | 1 |
| Parron, E | 1 |
| Barakat, M | 1 |
| Dludla, PV | 1 |
| Nkambule, BB | 1 |
| Mazibuko-Mbeje, SE | 1 |
| Nyambuya, TM | 1 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Ziqubu, K | 1 |
| Cirilli, I | 1 |
| Marcheggiani, F | 1 |
| Louw, J | 1 |
| Tiano, L | 1 |
| Wahba, NS | 2 |
| Ghareib, SA | 2 |
| Abdel-Ghany, RH | 2 |
| Abdel-Aal, M | 2 |
| Alsemeh, AE | 2 |
| Ahn, HK | 1 |
| Koo, KC | 1 |
| Bjekić-Macut, J | 1 |
| Vukašin, T | 1 |
| Velija-Ašimi, Z | 1 |
| Bureković, A | 1 |
| Zdravković, M | 1 |
| Andrić, Z | 1 |
| Branković, M | 1 |
| Crevar-Marinović, S | 1 |
| Madić, T | 1 |
| Stanojlović, O | 1 |
| Milutinović, DV | 1 |
| Livadas, S | 1 |
| Mastorakos, G | 1 |
| Portari, LHC | 1 |
| Correa-Silva, SR | 1 |
| Abucham, J | 1 |
| Gonzalez-Vergara, E | 1 |
| Mbara, KC | 1 |
| Mofo Mato, PE | 1 |
| Driver, C | 1 |
| Nzuza, S | 1 |
| Mkhombo, NT | 1 |
| Gcwensa, SK | 1 |
| Mcobothi, EN | 1 |
| Owira, PM | 1 |
| Jin, J | 1 |
| Liang, X | 1 |
| Wei, J | 2 |
| Ladeiras-Lopes, R | 3 |
| Sampaio, F | 3 |
| Leite, S | 1 |
| Santos-Ferreira, D | 1 |
| Vilela, E | 1 |
| Leite-Moreira, A | 2 |
| Bettencourt, N | 3 |
| Gama, V | 3 |
| Braga, P | 1 |
| Fontes-Carvalho, R | 3 |
| Li, P | 1 |
| Lu, B | 1 |
| Chen, Y | 2 |
| Tian, X | 1 |
| Han, B | 1 |
| Guo, Y | 1 |
| Xie, Z | 1 |
| Liao, Q | 1 |
| Alsheikh, HAM | 1 |
| Metge, BJ | 1 |
| Ha, CM | 1 |
| Hinshaw, DC | 1 |
| Mota, MSV | 1 |
| Kammerud, SC | 1 |
| Lama-Sherpa, T | 1 |
| Sharafeldin, N | 1 |
| Wende, AR | 1 |
| Samant, RS | 1 |
| Shevde, LA | 1 |
| Tapia, E | 1 |
| Villa-Guillen, DE | 1 |
| Chalasani, P | 1 |
| Centuori, S | 1 |
| Roe, DJ | 1 |
| Guillen-Rodriguez, J | 1 |
| Huang, C | 1 |
| Galons, JP | 1 |
| Thomson, CA | 1 |
| Altbach, M | 1 |
| Trujillo, J | 1 |
| Pinto, L | 1 |
| Martinez, JA | 1 |
| Algotar, AM | 1 |
| Chow, HS | 1 |
| Sabry, D | 1 |
| Whitburn, J | 1 |
| Edwards, CM | 1 |
| Sooriakumaran, P | 1 |
| Stagi, S | 1 |
| Ricci, F | 1 |
| Bianconi, M | 1 |
| Sammarco, MA | 1 |
| Municchi, G | 1 |
| Toni, S | 1 |
| Lenzi, L | 1 |
| Verrotti, A | 1 |
| de Martino, M | 1 |
| Kosuru, R | 1 |
| Singh, S | 2 |
| Glintborg, D | 2 |
| Andersen, M | 1 |
| Prokudina, ES | 1 |
| Maslov, LN | 1 |
| Ivanov, VV | 1 |
| Bespalova, ID | 1 |
| Pismennyi, DS | 1 |
| Voronkov, NS | 1 |
| Beysel, S | 1 |
| Unsal, IO | 1 |
| Kizilgul, M | 1 |
| Caliskan, M | 1 |
| Ucan, B | 1 |
| Cakal, E | 1 |
| Xu, Y | 1 |
| Shen, Z | 1 |
| Zhou, H | 1 |
| Siskind, D | 1 |
| Friend, N | 1 |
| Russell, A | 1 |
| McGrath, JJ | 1 |
| Lim, C | 1 |
| Patterson, S | 1 |
| Flaws, D | 1 |
| Stedman, T | 1 |
| Moudgil, V | 1 |
| Sardinha, S | 1 |
| Suetani, S | 1 |
| Kisely, S | 2 |
| Winckel, K | 1 |
| Baker, A | 1 |
| Paleari, L | 1 |
| Burhenne, J | 1 |
| Weiss, J | 1 |
| Foersch, S | 1 |
| Roth, W | 1 |
| Parodi, A | 1 |
| Gnant, M | 1 |
| Bachleitner-Hofmann, T | 1 |
| Scherer, D | 1 |
| Ulrich, CM | 1 |
| Stabuc, B | 1 |
| Puntoni, M | 1 |
| Coccia, G | 1 |
| Petrera, M | 1 |
| Haefeli, WE | 1 |
| DeCensi, A | 1 |
| Eckel, RH | 1 |
| Koh, KK | 1 |
| Alfawaz, HA | 1 |
| Wani, K | 1 |
| Alnaami, AM | 1 |
| Al-Saleh, Y | 1 |
| Aljohani, NJ | 1 |
| Al-Attas, OS | 1 |
| Alokail, MS | 1 |
| Kumar, S | 1 |
| Al-Daghri, NM | 1 |
| Denis, GV | 1 |
| Sebastiani, P | 1 |
| Bertrand, KA | 1 |
| Strissel, KJ | 1 |
| Tran, AH | 1 |
| Slama, J | 1 |
| Medina, ND | 1 |
| Andrieu, G | 1 |
| Palmer, JR | 1 |
| Bodur, S | 1 |
| Dundar, O | 1 |
| Kanat-Pektas, M | 1 |
| Kinci, MF | 1 |
| Tutuncu, L | 1 |
| Dorvash, MR | 1 |
| Khoshnood, MJ | 1 |
| Saber, H | 1 |
| Dehghanian, A | 1 |
| Mosaddeghi, P | 1 |
| Firouzabadi, N | 1 |
| Naguy, A | 1 |
| El-Sori, D | 1 |
| Ciric, D | 1 |
| Martinovic, T | 1 |
| Petricevic, S | 1 |
| Trajkovic, V | 1 |
| Bumbasirevic, V | 1 |
| Kravic-Stevovic, T | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Zhou, J | 1 |
| Massey, S | 1 |
| Story, D | 1 |
| Zayed, EA | 1 |
| AinShoka, AA | 1 |
| El Shazly, KA | 1 |
| Abd El Latif, HA | 1 |
| DeBoer, MD | 1 |
| Filipp, SL | 1 |
| Gurka, MJ | 1 |
| Wilmanns, JC | 1 |
| Pandey, R | 1 |
| Hon, O | 1 |
| Chandran, A | 1 |
| Schilling, JM | 1 |
| Forte, E | 1 |
| Wu, Q | 1 |
| Cagnone, G | 1 |
| Bais, P | 1 |
| Philip, V | 1 |
| Coleman, D | 1 |
| Kocalis, H | 1 |
| Archer, SK | 1 |
| Pearson, JT | 1 |
| Ramialison, M | 1 |
| Heineke, J | 1 |
| Patel, HH | 1 |
| Rosenthal, NA | 1 |
| Furtado, MB | 1 |
| Costa, MW | 1 |
| Kaplan, SA | 1 |
| Cortellini, M | 1 |
| Casagrande, A | 1 |
| Fornaciari, G | 1 |
| Del Sette, D | 1 |
| Gargano, G | 1 |
| Di Mauro, MG | 1 |
| Saibene, G | 1 |
| Bruno, E | 1 |
| Villarini, A | 1 |
| Venturelli, E | 1 |
| Berrino, F | 1 |
| Baldassari, I | 1 |
| Oliverio, A | 1 |
| Pasanisi, P | 1 |
| Malin, SK | 1 |
| Nightingale, J | 1 |
| Choi, SE | 1 |
| Chipkin, SR | 1 |
| Braun, B | 1 |
| Genovese, S | 2 |
| Passaro, A | 1 |
| Brunetti, P | 1 |
| Comaschi, M | 1 |
| Cucinotta, D | 1 |
| Egan, CG | 1 |
| Chinea, B | 1 |
| Bravi, F | 1 |
| Di Pietro, C | 1 |
| Ortúzar, N | 1 |
| Garnett, SP | 1 |
| Gow, M | 1 |
| Ho, M | 1 |
| Baur, LA | 1 |
| Noakes, M | 1 |
| Woodhead, HJ | 1 |
| Broderick, CR | 1 |
| Burrell, S | 1 |
| Chisholm, K | 1 |
| Halim, J | 1 |
| De, S | 1 |
| Steinbeck, K | 1 |
| Srinivasan, S | 1 |
| Ambler, GR | 1 |
| Kohn, MR | 1 |
| Cowell, CT | 1 |
| Desai, N | 2 |
| Roman, A | 1 |
| Rochelson, B | 1 |
| Gupta, M | 1 |
| Xue, X | 1 |
| Chatterjee, PK | 2 |
| Tam Tam, H | 1 |
| Metz, CN | 2 |
| Conteduca, V | 1 |
| Di Lorenzo, G | 1 |
| Bozza, G | 1 |
| Ardito, R | 1 |
| Aieta, M | 1 |
| Huang, MC | 2 |
| Kao, CF | 1 |
| Lin, SK | 1 |
| Kuo, PH | 1 |
| Chiu, CC | 2 |
| Lu, ML | 2 |
| Tesanović, S | 1 |
| Radman, M | 1 |
| Tesanović, D | 1 |
| Erzen, DJ | 1 |
| Hozo, I | 1 |
| Karatas, A | 1 |
| Özlü, T | 1 |
| Erdem, A | 1 |
| Yuan, H | 1 |
| Weng, C | 1 |
| Yang, Y | 1 |
| Huang, L | 1 |
| Xing, X | 1 |
| Florez, H | 1 |
| Temprosa, MG | 1 |
| Orchard, TJ | 2 |
| Mather, KJ | 1 |
| Marcovina, SM | 1 |
| Barrett-Connor, E | 1 |
| Horton, E | 1 |
| Saudek, C | 1 |
| Pi-Sunyer, XF | 1 |
| Ratner, RE | 1 |
| Goldberg, RB | 2 |
| Rizvi, AA | 2 |
| Nikolic, D | 2 |
| Sallam, HS | 1 |
| Montalto, G | 2 |
| Rizzo, M | 2 |
| Abate, N | 1 |
| Younossi, ZM | 1 |
| Reyes, MJ | 1 |
| Mishra, A | 1 |
| Mehta, R | 1 |
| Henry, L | 1 |
| Miazgowski, T | 1 |
| Dziwura-Ogonowska, J | 1 |
| Safranow, K | 1 |
| Iskierska, K | 1 |
| Widecka, K | 1 |
| Fruci, B | 1 |
| Giuliano, S | 1 |
| Mazza, A | 1 |
| Malaguarnera, R | 1 |
| Belfiore, A | 1 |
| Lyster, RL | 1 |
| Houle, SK | 1 |
| Gouni-Berthold, I | 1 |
| Berthold, HK | 1 |
| Calvert, JW | 1 |
| Xu, JP | 1 |
| Zhao, XZ | 1 |
| Sun, XJ | 1 |
| Xu, ZW | 1 |
| Song, SJ | 2 |
| Leite-Moreira, AF | 1 |
| Lexis, CP | 1 |
| van der Horst, IC | 1 |
| Soares Junior, JM | 1 |
| Sa, MF | 1 |
| Baracat, EC | 1 |
| Spritzer, PM | 1 |
| Tilg, H | 1 |
| Moschen, AR | 1 |
| Stiefelhagen, P | 2 |
| Elmadhun, NY | 3 |
| Sabe, AA | 1 |
| Lassaletta, AD | 3 |
| Chu, LM | 3 |
| Sellke, FW | 3 |
| Shan, W | 1 |
| Gu, C | 1 |
| Ning, C | 1 |
| Luo, X | 1 |
| Zhou, Q | 1 |
| Sicras-Mainar, A | 1 |
| Navarro-Artieda, R | 1 |
| Srinivasa, S | 1 |
| Wong, K | 1 |
| Fitch, KV | 1 |
| Petrow, E | 1 |
| Cypess, AM | 1 |
| Torriani, M | 2 |
| Grinspoon, SK | 1 |
| Zhao, X | 1 |
| Chen, M | 1 |
| Dai, Y | 1 |
| Xie, H | 1 |
| Luong, DQ | 1 |
| Oster, R | 1 |
| Ashraf, AP | 1 |
| Mkrtumian, AM | 1 |
| Markova, TN | 1 |
| Kichigin, VA | 1 |
| Podachina, SV | 1 |
| Zhuchkova, SM | 1 |
| Ünlü, M | 1 |
| Balta, Ş | 1 |
| Arslan, Z | 1 |
| Öztürk, C | 1 |
| Çelik, T | 1 |
| Iyisoy, A | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Brima, W | 1 |
| Eden, DJ | 1 |
| Mehdi, SF | 1 |
| Bravo, M | 1 |
| Wiese, MM | 1 |
| Stein, J | 1 |
| Almonte, V | 1 |
| Kurland, I | 1 |
| Pessin, JE | 1 |
| Zima, T | 1 |
| Tanowitz, HB | 1 |
| Weiss, LM | 1 |
| Roth, J | 1 |
| Nagajyothi, F | 1 |
| Martinez, MI | 1 |
| Ferri, A | 1 |
| Mateos, AM | 1 |
| Alegre, A | 1 |
| Mayer, SB | 1 |
| Evans, WS | 1 |
| Nestler, JE | 2 |
| Blanc, E | 1 |
| Ponce, C | 1 |
| Brodschi, D | 1 |
| Nepote, A | 1 |
| Barreto, A | 1 |
| Schnitman, M | 1 |
| Fossati, P | 1 |
| Salgado, P | 1 |
| Cejas, C | 1 |
| Faingold, C | 1 |
| Musso, C | 1 |
| Brenta, G | 1 |
| Dashdamirov, RL | 1 |
| Kuate, D | 1 |
| Kengne, AP | 1 |
| Biapa, CP | 1 |
| Azantsa, BG | 1 |
| Abdul Manan Bin Wan Muda, W | 1 |
| Zeb, MH | 1 |
| Baruah, A | 1 |
| Kossak, SK | 1 |
| Buttar, NS | 1 |
| Traussnigg, S | 1 |
| Kienbacher, C | 1 |
| Halilbasic, E | 1 |
| Rechling, C | 1 |
| Kazemi-Shirazi, L | 1 |
| Hofer, H | 1 |
| Munda, P | 1 |
| Trauner, M | 1 |
| Unwin, D | 1 |
| Tobin, S | 1 |
| Nakatsu, Y | 1 |
| Iwashita, M | 1 |
| Sakoda, H | 1 |
| Ono, H | 1 |
| Nagata, K | 1 |
| Matsunaga, Y | 1 |
| Fukushima, T | 1 |
| Fujishiro, M | 1 |
| Kushiyama, A | 1 |
| Kamata, H | 1 |
| Takahashi, S | 1 |
| Katagiri, H | 1 |
| Honda, H | 1 |
| Kiyonari, H | 1 |
| Uchida, T | 1 |
| Asano, T | 1 |
| Mayans, L | 1 |
| Jesus, C | 1 |
| Jesus, I | 1 |
| Agius, M | 1 |
| Ahmed, RH | 1 |
| Huri, HZ | 1 |
| Al-Hamodi, Z | 1 |
| Salem, SD | 1 |
| Muniandy, S | 1 |
| Zwolak, A | 1 |
| Szuster-Ciesielska, A | 1 |
| Daniluk, J | 1 |
| Słabczyńska, O | 1 |
| Kandefer-Szerszeń, M | 1 |
| De Sousa, SM | 1 |
| Norman, RJ | 1 |
| García Díaz, E | 1 |
| Guagnozzi, D | 1 |
| Gutiérrez, V | 1 |
| Mendoza, C | 1 |
| Maza, C | 1 |
| Larrañaga, Y | 1 |
| Perdomo, D | 1 |
| Godoy, T | 1 |
| Taleb, G | 1 |
| Chen, WH | 1 |
| Huang, WL | 1 |
| Hsieh, MH | 1 |
| Zawiejska, A | 1 |
| Wender-Ozegowska, E | 1 |
| Grewling-Szmit, K | 1 |
| Brazert, M | 1 |
| Brazert, J | 1 |
| Siskind, DJ | 1 |
| Leung, J | 1 |
| Russell, AW | 1 |
| Wysoczanski, D | 1 |
| Gandica, R | 1 |
| Zeitler, P | 1 |
| Bhansali, A | 1 |
| Mennella, C | 1 |
| Dickstein, DP | 1 |
| Farooq, R | 1 |
| Amin, S | 1 |
| Hayat Bhat, M | 1 |
| Malik, R | 1 |
| Wani, HA | 1 |
| Majid, S | 1 |
| Garibay-Nieto, N | 1 |
| Queipo-García, G | 1 |
| Alvarez, F | 1 |
| Bustos, M | 1 |
| Villanueva, E | 1 |
| Ramírez, F | 1 |
| León, M | 1 |
| Laresgoiti-Servitje, E | 1 |
| Duggirala, R | 1 |
| Macías, T | 1 |
| Cuevas, S | 1 |
| Jalife, A | 1 |
| Fonseca-Sánchez, M | 1 |
| Serratos, F | 1 |
| López-Alvarenga, JC | 1 |
| Andrade, C | 2 |
| Mostafa, DK | 1 |
| Nasra, RA | 1 |
| Zahran, N | 1 |
| Ghoneim, MT | 1 |
| Haddad, M | 1 |
| Knani, I | 1 |
| Bouzidi, H | 1 |
| Berriche, O | 1 |
| Hammami, M | 1 |
| Kerkeni, M | 1 |
| Patti, AM | 1 |
| Giglio, RV | 1 |
| Castellino, G | 1 |
| Li Volti, G | 1 |
| Caprio, M | 1 |
| Provenzano, V | 1 |
| Ceriello, A | 1 |
| Sheriba, NA | 1 |
| Ahmed, IZ | 1 |
| Abdelsalam, MM | 1 |
| Eid, YM | 1 |
| Mahdy, MM | 1 |
| Mansour, HK | 1 |
| Stover, L | 1 |
| Chi, J | 1 |
| Kelsberg, G | 1 |
| Safranek, S | 1 |
| Kasmari, AJ | 1 |
| Welch, A | 1 |
| Liu, G | 1 |
| Leslie, D | 1 |
| McGarrity, T | 1 |
| Riley, T | 1 |
| Felice, JI | 1 |
| Schurman, L | 1 |
| McCarthy, AD | 1 |
| Sedlinsky, C | 1 |
| Aguirre, JI | 1 |
| Cortizo, AM | 1 |
| Paul, AA | 1 |
| Dkhar, SA | 1 |
| Kamalanathan, S | 1 |
| Thabah, MM | 1 |
| George, M | 1 |
| Chandrasekaran, I | 1 |
| Gunaseelan, V | 1 |
| Selvarajan, S | 1 |
| Halimi, S | 1 |
| Debaty, I | 1 |
| Villaret, L | 1 |
| Muller, M | 1 |
| Gambineri, A | 2 |
| Semple, RK | 1 |
| Forlani, G | 1 |
| Genghini, S | 1 |
| Grassi, I | 1 |
| Hyden, CS | 1 |
| O'Rahilly, S | 1 |
| Drown, DJ | 1 |
| Cohen, P | 1 |
| Andreadis, EA | 1 |
| Katsanou, PM | 1 |
| Georgiopoulos, DX | 1 |
| Tsourous, GI | 1 |
| Yfanti, GK | 1 |
| Gouveri, ET | 1 |
| Diamantopoulos, EJ | 1 |
| Vuppalanchi, R | 1 |
| Chalasani, N | 2 |
| Helvaci, MR | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Yalcin, A | 1 |
| Brooks, JO | 1 |
| Chang, HS | 1 |
| Krasnykh, O | 1 |
| Gupta, AK | 1 |
| Smith, SR | 1 |
| Greenway, FL | 1 |
| Bray, GA | 1 |
| Wong, AK | 1 |
| Howie, J | 1 |
| Petrie, JR | 1 |
| Lang, CC | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Lima, LM | 1 |
| Wiernsperger, N | 3 |
| Kraemer-Aguiar, LG | 1 |
| Bouskela, E | 4 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Ferreira, CB | 1 |
| Cesaretti, ML | 1 |
| Ginoza, M | 1 |
| Kohlmann, O | 1 |
| Fontbonne, A | 1 |
| Diouf, I | 1 |
| Baccara-Dinet, M | 1 |
| Eschwege, E | 1 |
| Charles, MA | 1 |
| Guercio, G | 1 |
| Di Palma, MI | 1 |
| Pepe, C | 1 |
| Saraco, NI | 1 |
| Prieto, M | 1 |
| Saure, C | 1 |
| Mazza, C | 1 |
| Rivarola, MA | 1 |
| Belgorosky, A | 1 |
| Garruti, G | 1 |
| Depalo, R | 1 |
| Vita, MG | 1 |
| Lorusso, F | 1 |
| Giampetruzzi, F | 1 |
| Damato, AB | 1 |
| Giorgino, F | 1 |
| Housel, AK | 1 |
| Waterbury, N | 1 |
| Argo, TR | 1 |
| Kato, T | 1 |
| Sawai, Y | 1 |
| Kanayama, H | 1 |
| Taguchi, H | 1 |
| Terabayashi, T | 1 |
| Taki, F | 1 |
| Yamada, K | 1 |
| Yamazaki, Y | 1 |
| Hayakawa, N | 1 |
| Suzuki, A | 1 |
| Oda, N | 1 |
| Katada, N | 1 |
| Itoh, M | 1 |
| Cheang, KI | 1 |
| Huszar, JM | 1 |
| Best, AM | 1 |
| Sharma, S | 1 |
| Essah, PA | 1 |
| Souza-Mello, V | 1 |
| Gregório, BM | 1 |
| Cardoso-de-Lemos, FS | 1 |
| de Carvalho, L | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Pramyothin, P | 1 |
| Khaodhiar, L | 1 |
| Brouwers, MC | 1 |
| de Graaf, J | 1 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 1 |
| Stalenhoef, AF | 1 |
| Mamas, MA | 1 |
| Deaton, C | 1 |
| Rutter, MK | 1 |
| Yuille, M | 1 |
| Williams, SG | 1 |
| Ray, SG | 1 |
| New, J | 1 |
| Gibson, JM | 1 |
| Neyses, L | 1 |
| Jadeja, RN | 1 |
| Thounaojam, MC | 1 |
| Patel, VB | 1 |
| Devkar, RV | 1 |
| Ramachandran, AV | 1 |
| Ntaios, G | 1 |
| Savopoulos, C | 1 |
| Chatzopoulos, S | 1 |
| Mikhailidis, D | 1 |
| Hatzitolios, A | 1 |
| Oldham, J | 1 |
| Casulari, LA | 1 |
| Caldas, AD | 1 |
| Domingues Casulari Motta, L | 1 |
| Lofrano-Porto, A | 1 |
| Ohaeri, JU | 1 |
| Akanji, AO | 1 |
| Manikandan, S | 1 |
| Vani, NI | 1 |
| Morgante, G | 1 |
| Tosti, C | 1 |
| Orvieto, R | 1 |
| Musacchio, MC | 1 |
| Piomboni, P | 1 |
| De Leo, V | 1 |
| Clements, A | 1 |
| Gao, B | 1 |
| Yeap, SHO | 1 |
| Wong, MKY | 1 |
| Ali, SS | 1 |
| Gurney, H | 1 |
| Sharif, A | 1 |
| Pacifico, L | 1 |
| Anania, C | 1 |
| Martino, F | 1 |
| Poggiogalle, E | 1 |
| Arca, M | 1 |
| Chiesa, C | 1 |
| Gangale, MF | 1 |
| Miele, L | 1 |
| Lanzone, A | 1 |
| Sagnella, F | 1 |
| Martinez, D | 1 |
| Tropea, A | 1 |
| Moro, F | 1 |
| Morciano, A | 1 |
| Ciardulli, A | 1 |
| Palla, C | 1 |
| Pompili, M | 1 |
| Cefalo, C | 1 |
| Grieco, A | 1 |
| Apa, R | 1 |
| Singhal, J | 1 |
| Nagaprashantha, L | 1 |
| Vatsyayan, R | 1 |
| Awasthi, S | 1 |
| Singhal, SS | 1 |
| Nobes, JP | 1 |
| Langley, SE | 1 |
| Klopper, T | 1 |
| Russell-Jones, D | 1 |
| Laing, RW | 1 |
| Afanas'ev, VV | 1 |
| Striuk, RI | 1 |
| Arutiunian, SE | 1 |
| Eliseeva, LV | 1 |
| Bychkov, RA | 1 |
| Fitch, K | 1 |
| Abbara, S | 1 |
| Lee, H | 1 |
| Stavrou, E | 1 |
| Sacks, R | 1 |
| Michel, T | 1 |
| Hemphill, L | 1 |
| Grinspoon, S | 1 |
| Pérez, A | 1 |
| Franch, J | 1 |
| Cases, A | 1 |
| González Juanatey, JR | 1 |
| Conthe, P | 1 |
| Gimeno, E | 1 |
| Matali, A | 1 |
| Marshall, JC | 1 |
| Dunaif, A | 1 |
| Robich, MP | 1 |
| Feng, J | 1 |
| Burgess, TA | 1 |
| Laham, RJ | 1 |
| Sturek, M | 1 |
| Deji, N | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Tanaka, Y | 1 |
| Nishiyama, A | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Ahsan, T | 1 |
| Banu, Z | 1 |
| Puyó, AM | 1 |
| Borroni, JS | 1 |
| Boudou, S | 1 |
| Santander, Y | 1 |
| Carranza, A | 1 |
| Donoso, AS | 1 |
| Peredo, HA | 1 |
| Weickert, MO | 1 |
| Hodges, P | 1 |
| Tan, BK | 1 |
| Randeva, HS | 1 |
| Milewicz, A | 1 |
| Bagul, PK | 1 |
| Middela, H | 1 |
| Matapally, S | 1 |
| Padiya, R | 1 |
| Bastia, T | 1 |
| Madhusudana, K | 1 |
| Reddy, BR | 1 |
| Chakravarty, S | 1 |
| Banerjee, SK | 1 |
| Meaney, E | 2 |
| Sierra-Vargas, P | 1 |
| Meaney, A | 2 |
| Guzmán-Grenfell, M | 1 |
| Ramírez-Sánchez, I | 1 |
| Hicks, JJ | 1 |
| Olivares-Corichi, I | 1 |
| Ceballos, G | 2 |
| Hutcheson, R | 1 |
| Rocic, P | 1 |
| Bonny, AE | 1 |
| Appelbaum, H | 1 |
| Connor, EL | 1 |
| Cromer, B | 1 |
| DiVasta, A | 1 |
| Gomez-Lobo, V | 1 |
| Harel, Z | 1 |
| Huppert, J | 1 |
| Sucato, G | 1 |
| Mather, K | 1 |
| Lavrenko, AV | 1 |
| Shlykova, OA | 1 |
| Kutsenko, LA | 1 |
| Mamontova, TV | 1 |
| Kaĭdashev, IP | 1 |
| Mahmood, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Makolkin, VI | 2 |
| Podzolkov, VI | 2 |
| Napalkov, DA | 2 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 1 |
| Sprecher, DL | 1 |
| Decsi, T | 1 |
| Molnár, D | 1 |
| Akbar, DH | 1 |
| Slama, G | 1 |
| Picard, S | 1 |
| Glueck, CJ | 1 |
| Papanna, R | 1 |
| Wang, P | 1 |
| Goldenberg, N | 1 |
| Sieve-Smith, L | 1 |
| Vague, P | 1 |
| Després, JP | 1 |
| Libby, P | 1 |
| Henry, RR | 1 |
| Jermendy, G | 1 |
| Zimmer, P | 1 |
| Grant, RW | 2 |
| Meigs, JB | 2 |
| Herrmann, BL | 2 |
| Berg, C | 2 |
| Vogel, E | 1 |
| Nowak, T | 1 |
| Renzing-Koehler, K | 1 |
| Mann, K | 2 |
| Saller, B | 2 |
| Rao, SS | 1 |
| Disraeli, P | 1 |
| McGregor, T | 1 |
| Tankova, T | 1 |
| Cleasby, ME | 1 |
| Dzamko, N | 1 |
| Hegarty, BD | 1 |
| Cooney, GJ | 1 |
| Kraegen, EW | 1 |
| Ye, JM | 1 |
| Miranda, PJ | 1 |
| DeFronzo, RA | 1 |
| Califf, RM | 1 |
| Guyton, JR | 1 |
| Stratmann, M | 1 |
| Janssen, OE | 1 |
| Temprosa, M | 1 |
| Goldberg, R | 1 |
| Haffner, S | 2 |
| Ratner, R | 1 |
| Marcovina, S | 1 |
| Fowler, S | 1 |
| Bugianesi, E | 1 |
| Gentilcore, E | 1 |
| Manini, R | 2 |
| Natale, S | 2 |
| Vanni, E | 1 |
| Villanova, N | 1 |
| David, E | 1 |
| Rizzetto, M | 1 |
| Marchesini, G | 2 |
| Lester, JW | 1 |
| Fernandes, AW | 1 |
| Derosa, G | 4 |
| Gaddi, AV | 2 |
| Piccinni, MN | 4 |
| Ciccarelli, L | 4 |
| Salvadeo, S | 2 |
| Peros, E | 1 |
| Ghelfi, M | 2 |
| Ferrari, I | 4 |
| Cicero, AF | 4 |
| Wang, YJ | 1 |
| Zhu, WF | 1 |
| Wang, XK | 1 |
| Moreno Sánchez, D | 1 |
| Athyros, VG | 1 |
| Elisaf, M | 1 |
| Mikhailidis, DP | 1 |
| Distiller, LA | 1 |
| Landau, S | 1 |
| Joffe, B | 1 |
| Kramer, B | 1 |
| Blacking, L | 1 |
| Vitale, C | 1 |
| Mercuro, G | 1 |
| Cornoldi, A | 1 |
| Fini, M | 1 |
| Volterrani, M | 1 |
| Rosano, GM | 1 |
| Tang, T | 1 |
| Glanville, J | 1 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Barth, JH | 1 |
| Balen, AH | 1 |
| Sarinas, PS | 1 |
| Dube, DS | 1 |
| Anania, FA | 2 |
| Parekh, S | 1 |
| Shaukat, A | 1 |
| Agostini, F | 1 |
| Pricolo, F | 3 |
| Fogari, E | 1 |
| Fogari, R | 1 |
| Giugliano, D | 1 |
| Esposito, K | 1 |
| Mourão-Júnior, CA | 1 |
| Sá, JR | 1 |
| Guedes, OM | 1 |
| Dib, SA | 1 |
| Liang, L | 2 |
| Fu, JF | 2 |
| Zou, CC | 2 |
| Hong, F | 2 |
| Wang, CL | 2 |
| Wang, XM | 2 |
| de Aguiar, LG | 1 |
| Bahia, LR | 2 |
| Villela, N | 1 |
| Laflor, C | 1 |
| Sicuro, F | 1 |
| Bottino, D | 1 |
| Cool, B | 1 |
| Zinker, B | 1 |
| Chiou, W | 1 |
| Kifle, L | 1 |
| Cao, N | 1 |
| Perham, M | 1 |
| Dickinson, R | 1 |
| Adler, A | 1 |
| Gagne, G | 1 |
| Iyengar, R | 1 |
| Zhao, G | 1 |
| Marsh, K | 1 |
| Kym, P | 1 |
| Jung, P | 1 |
| Camp, HS | 1 |
| Frevert, E | 1 |
| Hoek, JB | 1 |
| Korenaga, M | 1 |
| Kawaguchi, K | 1 |
| Korenaga, K | 1 |
| Uchida, K | 1 |
| Sakaida, I | 1 |
| Kadayifci, A | 1 |
| Merriman, RB | 1 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
| D'Angelo, A | 2 |
| Ragonesi, PD | 2 |
| Salvadeo, SA | 2 |
| Montagna, L | 2 |
| Gravina, A | 2 |
| Paniga, S | 2 |
| Zhao, ZY | 1 |
| Ramachandran, A | 1 |
| Snehalatha, C | 1 |
| Satyavani, K | 1 |
| Sivasankari, S | 1 |
| Vijay, V | 1 |
| Hoppin, AG | 1 |
| Katz, ES | 1 |
| Kaplan, LM | 1 |
| Lauwers, GY | 1 |
| Schmidt-Trucksäss, A | 1 |
| Viberti, G | 1 |
| Lachin, J | 1 |
| Holman, R | 1 |
| Zinman, B | 1 |
| Kravitz, B | 1 |
| Heise, MA | 1 |
| Jones, NP | 1 |
| O'Neill, MC | 1 |
| Freed, MI | 1 |
| Herman, WH | 1 |
| Kraemer de Aguiar, LG | 2 |
| Laflor, CM | 1 |
| Bahia, L | 1 |
| Villela, NR | 2 |
| Bottino, DA | 2 |
| Bulcão, C | 2 |
| Giuffrida, FM | 1 |
| Ribeiro-Filho, FF | 2 |
| Ferreira, SR | 1 |
| Baptista, T | 2 |
| Sandia, I | 1 |
| Lacruz, A | 1 |
| Rangel, N | 2 |
| de Mendoza, S | 1 |
| Beaulieu, S | 2 |
| Contreras, Q | 1 |
| Galeazzi, T | 2 |
| Vargas, D | 1 |
| Hoteit, MA | 1 |
| Suzuki, T | 1 |
| Miwa, T | 1 |
| Notoya, Y | 1 |
| Odawara, M | 1 |
| Sañudo, A | 1 |
| Roberta Ferreira, SG | 1 |
| Harden, KA | 1 |
| Cowan, PA | 1 |
| Velasquez-Mieyer, P | 1 |
| Patton, SB | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Cylkowska, B | 1 |
| Hajduk, A | 1 |
| Kujawska-Danecka, H | 1 |
| Martínez-Bermejo, E | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Nieuwdorp, M | 1 |
| Stroes, ES | 1 |
| Kastelein, JJ | 1 |
| Haffner, SM | 1 |
| Khashab, M | 1 |
| Tetradze, L | 1 |
| Virsaladze, D | 1 |
| Javashvili, L | 1 |
| Kilasonia, L | 1 |
| Tananashvili, D | 1 |
| Nivoit, P | 1 |
| Wu, TH | 1 |
| Liu, HC | 1 |
| Paudel, B | 1 |
| Vaikkakara, S | 1 |
| Al-Ozairi, E | 1 |
| Lim, E | 1 |
| Advani, A | 1 |
| Ball, SG | 1 |
| James, RA | 1 |
| Quinton, R | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Iwasaki, Y | 1 |
| Takayasu, S | 1 |
| Nishiyama, M | 1 |
| Tsugita, M | 1 |
| Taguchi, T | 1 |
| Asai, M | 1 |
| Yoshida, M | 1 |
| Kambayashi, M | 1 |
| Hashimoto, K | 1 |
| Santomauro Júnior, AC | 1 |
| Ugolini, MR | 1 |
| Santomauro, AT | 1 |
| Souto, RP | 1 |
| Vela, A | 1 |
| Samaniego, V | 1 |
| Asbún, J | 1 |
| Zempoalteca, JC | 1 |
| Elisa, ZN | 1 |
| Emma, MN | 1 |
| Guzman, M | 1 |
| Hicks, J | 1 |
| Uzcátegui, E | 1 |
| El Fakih, Y | 1 |
| de Baptista, EA | 1 |
| Scheen, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age[NCT02417090] | 173 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction[NCT05847244] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Recruiting | ||
| Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk[NCT02028221] | Phase 2 | 151 participants (Actual) | Interventional | 2014-03-07 | Completed | ||
| ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis[NCT02328677] | 5,000 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau[NCT05591339] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome[NCT02960711] | Phase 3 | 1,600 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients[NCT01300637] | 60 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | |||
| A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study[NCT04231838] | 576 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy[NCT05301231] | 450 participants (Anticipated) | Observational [Patient Registry] | 2022-08-01 | Not yet recruiting | |||
| Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi[NCT04698122] | 75 participants (Actual) | Observational | 2021-05-27 | Completed | |||
| Investigation of the Effect of Calisthenic Exercise Training Combined With Aerobic Exercise on Exercise Tolerance, Physical Fitness and Plasma Lipid Profile in Patients With Dyslipidemia[NCT06008912] | 24 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients[NCT02063802] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes[NCT03377335] | Phase 4 | 186 participants (Anticipated) | Interventional | 2017-12-22 | Active, not recruiting | ||
| Effects of Liraglutide on Cardio-Metabolic Risk Markers[NCT01715428] | 300 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS[NCT00219440] | Phase 4 | 60 participants (Anticipated) | Interventional | 2003-02-28 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Strategies for the Treatment of HIV Associated Metabolic Syndrome[NCT00399360] | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | |||
| Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial[NCT06105060] | Early Phase 1 | 160 participants (Anticipated) | Interventional | 2023-12-17 | Not yet recruiting | ||
| Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome[NCT02695186] | 180 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| Physical Activity and Sedentary Behavior Change; Impact on Lifestyle Intervention Effects for Diabetes Translation[NCT02467881] | 308 participants (Actual) | Interventional | 2015-09-30 | Active, not recruiting | |||
| Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur[NCT00969956] | 17 participants (Actual) | Observational | 2012-04-30 | Terminated (stopped due to Local regulations) | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.[NCT04148183] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2004-01-01 | Completed | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in dense breast volume at 12 months (NCT02028221)
Timeframe: Baseline, 12 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -12.11 |
| Metformin | -14.75 |
change of dense breast volume at 6 months (NCT02028221)
Timeframe: baseline, 6 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -5.45 |
| Metformin | -13.71 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | kg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 101.5 | 99.6 | 99.3 |
| Placebo | 102.3 | 102.1 | 103.2 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.170 | 0.169 | 0.165 |
| Placebo | 0.178 | 0.178 | 0.171 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | uIU/ml (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 13.5 | 11.9 | 11.7 |
| Placebo | 14.6 | 14.0 | 13.1 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.028 | 0.025 | 0.026 |
| Placebo | 0.023 | 0.022 | 0.021 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 111.2 | 108.9 | 108.3 |
| Placebo | 110.3 | 111.6 | 111.8 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm2 (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -22.6 |
| Lifestyle Modification and Placebo | -1.5 |
| No Lifestyle Modification and Metformin | -28.2 |
| Lifestyle Modification and Metformin | -35.0 |
High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/l (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.27 |
| Lifestyle Modification and Placebo | -1.19 |
| No Lifestyle Modification and Metformin | 0.47 |
| Lifestyle Modification and Metformin | -1.92 |
A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | ml/kg/min (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.7 |
| Lifestyle Modification and Placebo | 2.0 |
| No Lifestyle Modification and Metformin | -1.3 |
| Lifestyle Modification and Metformin | 3.7 |
Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.02 |
| Lifestyle Modification and Placebo | -0.02 |
| No Lifestyle Modification and Metformin | 0.00 |
| Lifestyle Modification and Metformin | 0.03 |
Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | Agatston score (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 43 |
| Lifestyle Modification and Placebo | 19 |
| No Lifestyle Modification and Metformin | 1 |
| Lifestyle Modification and Metformin | -4 |
Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -7 |
| Lifestyle Modification and Placebo | 3 |
| No Lifestyle Modification and Metformin | 2 |
| Lifestyle Modification and Metformin | -7 |
High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -2 |
| Lifestyle Modification and Placebo | 2 |
| No Lifestyle Modification and Metformin | 0 |
| Lifestyle Modification and Metformin | 4 |
Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mmol/kg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 0.6 |
| Lifestyle Modification and Placebo | -0.4 |
| No Lifestyle Modification and Metformin | 0.8 |
| Lifestyle Modification and Metformin | 0.1 |
Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -5 |
| Lifestyle Modification and Placebo | -2 |
| No Lifestyle Modification and Metformin | -2 |
| Lifestyle Modification and Metformin | -6 |
Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -1.9 |
| Lifestyle Modification and Placebo | -0.1 |
| No Lifestyle Modification and Metformin | 0.3 |
| Lifestyle Modification and Metformin | -1.4 |
74 reviews available for metformin and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic Disorders in Multiple Myeloma.
Topics: Cell Proliferation; Cytokines; Energy Metabolism; Glycolysis; Humans; Metabolic Diseases; Metabolic | 2021 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Metabolic syndrome in children.
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Cardiovascular Diseases; Child; Dipeptidyl-Pepti | 2020 |
Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials.
Topics: Adipokines; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Sy | 2021 |
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2020 |
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metabolic Syndrome; Metformin; Polycystic Ovar | 2021 |
Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cardiovascular Diseases; COVID-19; COVID-19 D | 2021 |
Metformin and Prostate Cancer: a New Role for an Old Drug.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Male; Metabolic Syndrome; Metformin; Prostatic | 2017 |
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal | 2017 |
[The Role of Reactive Oxygen Species in the Pathogenesis of Adipocyte Dysfunction in Metabolic Syndrome. Prospects of Pharmacological Correction].
Topics: Adipocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Oxidativ | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Disea | 2018 |
Metformin: An Old Drug with New Applications.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metform | 2018 |
Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Topics: Body Composition; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Gro | 2013 |
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Gluco | 2014 |
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Me | 2014 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
Topics: Acarbose; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-C | 2014 |
Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
Topics: Adolescent; Female; Humans; Insulin Resistance; Life Style; Menopause; Metabolic Syndrome; Metformin | 2014 |
Microbiota and diabetes: an evolving relationship.
Topics: Diabetes Mellitus, Type 2; Diet Therapy; Feces; Humans; Hypoglycemic Agents; Immunity, Innate; Intes | 2014 |
Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Re | 2015 |
Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
Topics: Androgens; Anovulation; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2015 |
Chemoprevention in Barrett's Esophagus: Current Status.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy | 2015 |
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre | 2015 |
Metabolic Syndrome: Insulin Resistance and Prediabetes.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Humans; Hypoglycemic Agent | 2015 |
A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics.
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; England; Evidence-Based Medicine; Humans; Li | 2015 |
Metabolic syndrome, diet and exercise.
Topics: Bariatric Surgery; Diet; Diet Therapy; Exercise; Exercise Therapy; Female; Humans; Hydroxymethylglut | 2016 |
Endocrine and metabolic characteristics in polycystic ovary syndrome.
Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S | 2016 |
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
Topics: Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Clozapine; Fasting; Humans; Hypog | 2016 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; | 2016 |
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Fructose; Humans; | 2016 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; H | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
Metabolic risks in older adults receiving second-generation antipsychotic medication.
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antipsychotic Agents; Cardiovascular Diseas | 2009 |
AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cardiovascular Diseases; Enzyme Activatio | 2009 |
Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment.
Topics: Adipokines; Adipose Tissue; Animals; Female; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2009 |
Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Randomized Control | 2009 |
Metabolic syndrome with the atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Clozapine; Humans; Metabolic Syndrom | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
Topics: Blood Glucose; Fatty Acids; Glucose Intolerance; Heart Failure; Humans; Hypoglycemic Agents; Increti | 2010 |
Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Clinical Trials as Topic; Fibric Acids; Homocys | 2011 |
Metabolic syndrome in severe mental disorders.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Environment; Humans; Lif | 2011 |
Metformin in prostate cancer: two for the price of one.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syn | 2011 |
Management of metabolic syndrome in children and adolescents.
Topics: Adolescent; Antioxidants; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2011 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; | 2012 |
Metformin: the hidden chronicles of a magic drug.
Topics: Animals; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Metformin; Neo | 2013 |
[Metabolic syndrome from the point of view of a cardiologist: diagnosis, non drug and drug treatment].
Topics: Antihypertensive Agents; Cardiology; Exercise; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metf | 2002 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
Insulin resistance syndrome in children : pathophysiology and potential management strategies.
Topics: Child; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Metformin; Obes | 2003 |
[Metabolic syndrome: to observe or to act?].
Topics: Body Constitution; Humans; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistan | 2003 |
Is metformin more than an oral hypoglycaemic agent?
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; H | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
Metformin and vascular protection: a cardiologist's view.
Topics: Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resi | 2003 |
[Is type-2 diabetes mellitus preventable?].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Anti-Obesity Agents; Antihypertensive Agents; Cl | 2003 |
Should the insulin resistance syndrome be treated in the elderly?
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Geriatrics; Humans; Hypogly | 2004 |
Current indications for metformin therapy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2003 |
Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
Topics: Adult; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome; | 2005 |
Management of the metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2005 |
Insulin-sensitizing agents in polycystic ovary syndrome.
Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2006 |
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit | 2006 |
[The metabolic syndrome and sports].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Clinical Trials as Topic; Diabetes Mellitus; Ener | 2006 |
Treatment of fibrosis in nonalcoholic fatty liver disease.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age | 2007 |
[Biguanides].
Topics: Biguanides; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin | 2006 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Unmet needs in controlling metabolic disease.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Hyp | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
Metabolic syndrome: are we at risk?
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2007 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
[Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Diet; Energy Metabolism; Exercise; Glucose | 2008 |
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitu | 2008 |
69 trials available for metformin and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial.
Topics: Female; Humans; Insulin; Insulin Resistance; Kidney; Metabolic Syndrome; Metformin; Polycystic Ovary | 2021 |
Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study.
Topics: Female; Gastrointestinal Microbiome; Humans; Inulin; Male; Metabolic Syndrome; Metformin; Middle Age | 2022 |
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Humans; Insulins; Male; Metabolic Syndrome; Metformin; Prosta | 2023 |
Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors.
Topics: Adult; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Exercise; Exerci | 2020 |
Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels.
Topics: Adult; Anti-Mullerian Hormone; Clomiphene; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydrotes | 2020 |
Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study.
Topics: Adolescent; Body Mass Index; Body Weight; C-Reactive Protein; Carotid Intima-Media Thickness; Child; | 2019 |
Effect of metformin on cardiovascular risk factors in middle-aged Thai women with metabolic syndrome: A randomized placebo-controlled trial.
Topics: Blood Glucose; Cardiovascular Diseases; Double-Blind Method; Female; Heart Disease Risk Factors; Hum | 2020 |
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2020 |
Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; | 2021 |
A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
Topics: Adiposity; Breast Density; Breast Neoplasms; Feasibility Studies; Female; Humans; Mammography; Metab | 2021 |
Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome.
Topics: Adolescent; Child; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; M | 2017 |
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Double-Bli | 2018 |
Effects of Different Dietary and Lifestyle Modification Therapies on Metabolic Syndrome in Prediabetic Arab Patients: A 12-Month Longitudinal Study.
Topics: Adult; Arabs; Biomarkers; Blood Glucose; Chi-Square Distribution; Diet, Healthy; Exercise; Female; G | 2018 |
The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study.
Topics: Adult; Androstenes; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; D | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
Topics: Adiposity; Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Dou | 2013 |
Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fe | 2013 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Topics: Adult; Body Weight; Clozapine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Metabol | 2013 |
Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention.
Topics: Adult; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Male; Metabolic Syndrome; | 2013 |
Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Topics: Age Factors; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2014 |
Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
Topics: Adult; Aged; Biomarkers; Cardiotonic Agents; Creatine Kinase, MB Form; Humans; Metabolic Syndrome; M | 2014 |
METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial.
Topics: Adult; Aged; Diastole; Echocardiography; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle | 2014 |
Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.
Topics: Adult; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Endometrial Hyperplasia; Female; | 2014 |
Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Body Composition; Body Mass Index; Female; Fibroblas | 2015 |
Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance.
Topics: Aberrant Crypt Foci; Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; | 2015 |
[Efficacy of metformin in abdominal obesity].
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Insulin Re | 2014 |
Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: results of a prospective, randomised study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglyce | 2016 |
Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2016 |
Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Blood Glucose; Body Composition; Cardiovascular Diseases; Child; Double-Blin | 2017 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2 | 2016 |
Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fetuins; Hum | 2018 |
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Topics: Adult; Aged; Anthropometry; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Reducing; Fe | 2009 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Bl | 2009 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; | 2009 |
Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, | 2009 |
Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome.
Topics: Adult; Body Mass Index; Diet, Reducing; Humans; Hypoglycemic Agents; Hypogonadism; Life Style; Longi | 2010 |
Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome.
Topics: Adult; Androgens; Asthenozoospermia; Humans; Hypoglycemic Agents; Infertility, Male; Insulin Resista | 2011 |
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Behavior Therapy; Blood Glucose; Disease-Free Surviva | 2012 |
Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Female; HIV Infections; Humans; Hypoglycemic Agents; Life | 2012 |
Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study.
Topics: Aryldialkylphosphatase; Carotid Intima-Media Thickness; Case-Control Studies; Humans; Hypoglycemic A | 2012 |
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.
Topics: Blood Glucose; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Hu | 2003 |
Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Topics: Aged; Arginine; Blood Glucose; Blood Pressure; Body Composition; Body Constitution; Body Weight; Dia | 2004 |
Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Topics: Adiponectin; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fi | 2005 |
[Study on the effect of qinggan jiangtang tablet in improving the insulin resistance in patients with multiple metabolic syndrome].
Topics: Adult; Aged; Double-Blind Method; Drugs, Chinese Herbal; Female; Humans; Hypoglycemic Agents; Insuli | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug | 2005 |
Metformin improves endothelial function in patients with metabolic syndrome.
Topics: Brachial Artery; Endothelium, Vascular; Female; Homeostasis; Humans; Hypoglycemic Agents; Image Proc | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dou | 2005 |
Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, | 2006 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2006 |
Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme.
Topics: Adult; Diabetes Mellitus; Female; Glucose Intolerance; Humans; India; Insulin Resistance; Life Style | 2007 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; | 2006 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 2007 |
Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
Topics: Adult; Capillaries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind | 2007 |
Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
Topics: Adiponectin; Adolescent; Adult; Aged; Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; | 2007 |
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive P | 2007 |
Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response R | 2007 |
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].
Topics: Adult; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Rosiglitazone; Thia | 2007 |
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Female; Glucos | 2008 |
Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study.
Topics: Adult; Arginine; Carotid Arteries; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Me | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
134 other studies available for metformin and Metabolic Syndrome
| Article | Year |
|---|---|
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Female; Hyperinsulinism; Hypoglycemic Agents; Insu | 2021 |
Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animal Feed; Animals; Antio | 2021 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, T | 2021 |
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
Topics: Animals; Diet, High-Fat; Female; Kidney Diseases; Liraglutide; Male; Metabolic Syndrome; Metformin; | 2021 |
Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome.
Topics: Arteries; Blood Flow Velocity; Blood Glucose; Body Mass Index; Endothelium, Vascular; Female; Glucos | 2022 |
Does Metformin Treatment in Pediatric Population Cause Vitamin B12 Deficiency?
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Homocysteine; Humans; Male; Metabolic Syndrome | 2022 |
Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials.
Topics: Anthropometry; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2022 |
Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome.
Topics: Animals; Gastrointestinal Microbiome; Glucose Intolerance; Metabolic Syndrome; Metformin; Rats; Rats | 2022 |
Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome-Associated Gut Microbiome.
Topics: Butyrates; Clostridiales; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Metabolic | 2022 |
Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Hyperglycemia; Hyp | 2022 |
Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adenylosuccinate Synthase; AMP-Activated Protein Ki | 2022 |
Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats.
Topics: Animals; Fructose; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mus | 2022 |
Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome.
Topics: Animals; Atorvastatin; Liver; Male; Metabolic Syndrome; Metformin; Models, Theoretical; Non-alcoholi | 2023 |
Metabolic complications of glucocorticoids. Prevention by metformin.
Topics: Glucocorticoids; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin | 2023 |
Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators.
Topics: Adipokines; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Heart Dis | 2023 |
Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
Topics: Aged; Animals; Female; Hypoglycemic Agents; Liraglutide; Male; Metabolic Syndrome; Metformin; Rats; | 2023 |
Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Diet, High-Fat; Fatty Liver; Gastrointestinal Microbiome | 2019 |
Effects of metformin on recognition memory and hippocampal neuroplasticity in rats with metabolic syndrome.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain-Derived Neurotrophic Factor; Hippocampus; Hypog | 2020 |
Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Diet, High-Fat; Epoprostenol; Heart | 2020 |
Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Therapy, Combination; Hypoglycemic Age | 2020 |
A comparison of the effects of Stevia extract and metformin on metabolic syndrome indices in rats fed with a high-fat, high-sucrose diet.
Topics: Animals; Diet, High-Fat; Metabolic Syndrome; Metformin; Plant Extracts; Rats; Stevia; Sucrose | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Dise | 2020 |
Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Cholecalciferol; Dipeptidyl-Peptidase IV Inhibitors; Male; M | 2021 |
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; H | 2022 |
Metforminium Decavanadate (MetfDeca) Treatment Ameliorates Hippocampal Neurodegeneration and Recognition Memory in a Metabolic Syndrome Model.
Topics: Animals; Catalase; Drug Combinations; Hippocampus; Inflammation; Male; Memory; Metabolic Syndrome; M | 2021 |
A New Mutation of the INSR Gene in a 13-Year-Old Girl with Severe Insulin Resistance Syndrome in China.
Topics: Adolescent; Antigens, CD; Female; Humans; Introns; Metabolic Syndrome; Metformin; Point Mutation; Re | 2021 |
Chickpea Extract Ameliorates Metabolic Syndrome Symptoms via Restoring Intestinal Ecology and Metabolic Profile in Type 2 Diabetic Rats.
Topics: Animals; Cicer; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dysbiosi | 2021 |
Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Mellitus, Experimental; Female; | 2021 |
Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome.
Topics: Adamantane; Animals; Cholecalciferol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2022 |
Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats.
Topics: Animals; beta-Cyclodextrins; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
The effects of metformin in type 1 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; C-Peptide; Case-Control Studies; Diabetes Mellitus, T | 2018 |
Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Insulin-Li | 2018 |
High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.
Topics: Colon; Diabetes Mellitus; Humans; Hypoglycemic Agents; Intestinal Absorption; Metabolic Syndrome; Me | 2018 |
Inflammatory signatures distinguish metabolic health in African American women with obesity.
Topics: Biomarkers; Black or African American; Chemokines; Cytokines; Diabetes Mellitus, Type 2; Female; Gly | 2018 |
Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice.
Topics: Animals; Calcinosis; Cholagogues and Choleretics; Cholesterol; Diabetes Mellitus, Type 2; Diet, High | 2018 |
Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?
Topics: Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Weight Gain | 2018 |
Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, High-Fat; Hydroxymethylglutaryl-CoA | 2018 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
Improvement of insulin resistance via increase of GLUT4 and PPARγ in metabolic syndrome-induced rats treated with omega-3 fatty acid or l-carnitine.
Topics: Adiposity; Animals; Carnitine; Diet, Carbohydrate Loading; Diet, High-Fat; Dietary Supplements; Fatt | 2018 |
Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease.
Topics: Animals; Cardiac Output; Energy Metabolism; Heart Defects, Congenital; Hypoglycemic Agents; Male; Me | 2019 |
Re: Effects of Metformin on Prostatic Tissue of Rats with Metabolic Syndrome and Benign Prostatic Hyperplasia.
Topics: Animals; Disease Models, Animal; Humans; Male; Metabolic Syndrome; Metformin; Prostatic Hyperplasia; | 2019 |
A management system for randomized clinical trials: A novel way to supply medication.
Topics: Aged; Clinical Trials, Phase III as Topic; Female; Humans; Hypoglycemic Agents; Male; Management Inf | 2019 |
The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic | 2013 |
Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome.
Topics: Animals; Diet, High-Fat; Dietary Carbohydrates; Female; Fetus; Inflammation; Interleukin-6; Male; Me | 2013 |
Reply: To PMID 23659985.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Maternal metformin, obesity, and metabolic syndrome: the contribution of autonomic nervous system function.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin.
Topics: Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Models, Biological; Resistin; Rosiglitazo | 2013 |
Changes in adiponectin level and fat distribution in patients with type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Aged; Blood Glucose; Body Fat Distribution; Body Weight; Diabetes Melli | 2014 |
Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia.
Topics: Diabetes Mellitus; Drug Prescriptions; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; | 2013 |
Treating percutaneous coronary intervention-related myocardial injury with metformin.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2014 |
Metformin for cardiovascular disease: promise still unproven.
Topics: Carotid Intima-Media Thickness; Coronary Disease; Female; Humans; Hypoglycemic Agents; Male; Metabol | 2014 |
[Should insulin resistance be always treated in Polycystic Ovary Syndrome?].
Topics: Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Polycystic Ovary Syndrome | 2014 |
[The secret world of the microbiom. Do bacteria make us fat?].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Intestines; Metabolic Syndrome; Metformin; Microbiota; O | 2014 |
Metformin mitigates apoptosis in ischemic myocardium.
Topics: Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Forkhead Transcription Factors; Hypo | 2014 |
Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diab | 2014 |
Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome.
Topics: Adolescent; Body Mass Index; Body Weight; Child; Dyslipidemias; Humans; Hypoglycemic Agents; Metabol | 2015 |
The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2015 |
Response to the paper by Ünlü et al. entitled 'The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts'.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2015 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
The brighter (and evolutionarily older) face of the metabolic syndrome: evidence from Trypanosoma cruzi infection in CD-1 mice.
Topics: Adipose Tissue, White; Adiposity; Animals; Cell Line; Chagas Disease; Cytokines; Energy Metabolism; | 2015 |
[Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle].
Topics: Aged, 80 and over; Anthropometry; Blood Glucose; Diet Records; Diet, Diabetic; Diet, Fat-Restricted; | 2014 |
Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome.
Topics: Aged; Aged, 80 and over; Anthropometry; Argentina; Body Mass Index; Cohort Studies; Cross-Sectional | 2015 |
[Results of combined therapy of stable 2-3 FC angina of effort with metabolic syndrome including metformin].
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cardiovascular Agents; Drug Therapy, Combina | 2014 |
Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Fruit; Hypoglycemic Agents; | 2015 |
A patient request for some "deprescribing".
Topics: Abdominal Pain; Diabetes Mellitus, Type 2; gamma-Glutamyltransferase; Humans; Hypoglycemic Agents; L | 2015 |
Prolyl isomerase Pin1 negatively regulates AMP-activated protein kinase (AMPK) by associating with the CBS domain in the γ subunit.
Topics: AMP-Activated Protein Kinases; Animals; Gene Expression Regulation; Gene Expression Regulation, Enzy | 2015 |
Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fasting; Female; Glucagon-L | 2015 |
Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate.
Topics: Cytokines; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Ketoglutari | 2015 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gl | 2016 |
Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combination; Dystonia; Female; Hum | 2016 |
Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Drug Hypersensitivity; Humans; Hypersensitivity, Imme | 2017 |
Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs.
Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leptin; Male; Me | 2017 |
Pleiotropic protective effects of Vitamin D against high fat diet-induced metabolic syndrome in rats: One for all.
Topics: Animals; Biomarkers; Body Weight; Calcium; Cytoprotection; Diet, High-Fat; Drug Interactions; Hypert | 2016 |
Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunoso | 2016 |
Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues.
Topics: Acidosis, Lactic; Antipsychotic Agents; Cohort Studies; Diabetes Mellitus, Type 2; Gastrointestinal | 2016 |
Clinical Inquiry: Which patients with metabolic syndrome benefit from metformin?
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; | 2016 |
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human | 2017 |
Effects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment.
Topics: Adipocytes; Animals; Bone and Bones; Bone Density; Cell Differentiation; Cells, Cultured; Fructose; | 2017 |
Effect of metformin on exercise capacity in metabolic syndrome.
Topics: Exercise Test; Exercise Therapy; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin | 2017 |
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Hypoglycemic Agents; Lamin Type A; Metabolic Syn | 2008 |
Metformin: effective in the prevention of new-onset type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Early Diagnosis; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
Topics: Androgen Antagonists; Diabetes Mellitus, Type 2; Humans; Male; Metabolic Syndrome; Metformin; Obesit | 2009 |
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Topics: Body Mass Index; Body Size; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Greece; | 2009 |
Treatment of white coat hypertension with metformin.
Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human | 2008 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
[Metformin effects upon blood pressure and glucose metabolism of monossodium glutamate induced-obese spontaneously hypertensive rats].
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Hypoglycemic Agents; Male; Metabolic | 2009 |
Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency.
Topics: Androgen Antagonists; Androgens; Aromatase; Child; Diabetes Mellitus, Type 2; Estrogen Replacement T | 2009 |
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol, HDL; Female; Humans; Hypoglycemic Agents; Insul | 2009 |
[Discharge letter with therapeutic recommendations: you have to sort out!].
Topics: Antihypertensive Agents; Drug Therapy; Drug Therapy, Combination; Drug-Related Side Effects and Adve | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fat | 2010 |
Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats.
Topics: Animals; Blood Pressure; Clerodendrum; Disease Models, Animal; Dyslipidemias; Insulin Resistance; Li | 2010 |
Countering side effects.
Topics: Antipsychotic Agents; Body Weight; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Psych | 2010 |
Holiday reading: Learning medicine through riddles.
Topics: Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin | 2010 |
Should metformin be our antiglycemic agent of choice post-transplantation?
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type | 2011 |
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Liver; Metabolic Syndrome; Metformin; O | 2011 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Hepta | 2011 |
Metabolic syndrome and mental illness. Weight gain and other unhealthy attributes increase risk of diabetes and heart disease.
Topics: Antipsychotic Agents; Blood Glucose; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, | 2011 |
[Reactive-dystrophic processes in salivary glands (sialoadenoses) running on the background of metabolic syndrome].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Diabetes Mellitus, Type 2; Female; Glucose Toler | 2011 |
[Relationship between the degree of glycemic control and diabetes characteristics and hyperglycemia treatment in type 2 diabetes. DIABES Study].
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Dr | 2012 |
Should all women with PCOS be treated for insulin resistance?
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metab | 2012 |
Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia.
Topics: Animals; Collateral Circulation; Coronary Vessels; Diet, High-Fat; Hemodynamics; Hypoglycemic Agents | 2012 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
Male partial hypogonadotrophic hypogonadism with gynaecomastia and metabolic syndrome.
Topics: Follow-Up Studies; Genital Diseases, Male; Gonadotropins; Gynecomastia; Humans; Hypogonadism; Male; | 2012 |
Metformin reduces vascular production of vasoconstrictor prostanoids in fructose overloaded rats.
Topics: Animals; Aorta, Thoracic; Fructose; Male; Mesenteric Arteries; Metabolic Syndrome; Metformin; Oxidat | 2012 |
Menopausal obesity and metabolic syndrome - PolSenior study.
Topics: Age of Onset; Aged; Aged, 80 and over; Anthropometry; Cardiovascular Diseases; Cohort Studies; Diabe | 2012 |
Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats.
Topics: Animals; Ascorbic Acid; Blood Glucose; Body Weight; Catalase; Eating; Fructose; Glucose Tolerance Te | 2012 |
Clinical variability in approaches to polycystic ovary syndrome.
Topics: Adolescent; Contraceptives, Oral; Cross-Sectional Studies; Data Collection; Exercise; Feeding Behavi | 2012 |
Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Coronary Circulation; Disease Models, Animal; Energy Metabol | 2013 |
[Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism].
Topics: Aged; Alleles; Body Weight; Case-Control Studies; Coronary Disease; Cytokines; Diabetes Mellitus, Ty | 2012 |
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
Topics: Adult; Blood Glucose; Blood Pressure; Body Constitution; Cholesterol, HDL; Diabetes Mellitus, Type 2 | 2003 |
[Physical activity in hyperglycemia and type 2 diabetes. Effective but still underutilized].
Topics: Adult; Aged; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Exercise; Female | 2003 |
Impaired glucose tolerance and impaired fasting glucose.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes, Gestational; Disease Progression; Female; Glucose Intole | 2004 |
[Assessment of efficacy of combined therapy with antihypertensive agents and biguanides in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cholesterol, HDL; Data Int | 2004 |
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms.
Topics: Animals; Gene Expression Regulation; Gluconeogenesis; Glucose; Glucose Clamp Technique; Hyperinsulin | 2004 |
Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
Topics: Arteriosclerosis; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Endotheli | 2005 |
Summaries for patients. The effect of diet and exercise or metformin on the metabolic syndrome.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic | 2005 |
The 'worried-well', insulin resistance and metformin therapy.
Topics: Humans; Hypoglycemic Agents; Insulin; Metabolic Syndrome; Metformin | 2005 |
The Diabetes Prevention Program and the metabolic syndrome.
Topics: Combined Modality Therapy; Diet, Reducing; Exercise Therapy; Humans; Hypoglycemic Agents; Life Style | 2005 |
The Diabetes Prevention Program and the metabolic syndrome.
Topics: Combined Modality Therapy; Diet, Reducing; Exercise Therapy; Fatty Liver; Humans; Hypoglycemic Agent | 2005 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Heal | 2006 |
Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Drug Ther | 2006 |
[Metformin hydrochloride ameliorates adiponectin levels and insulin sensitivity in adolescents with metabolic syndrome].
Topics: Adiponectin; Adolescent; Alanine Transaminase; Blood Glucose; Blood Pressure; Case-Control Studies; | 2006 |
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cell Line; Diabetes Mellitus, Type 2; Di | 2006 |
Metformin and the fate of fat.
Topics: Animals; Disease Models, Animal; Fats; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabo | 2006 |
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2006 |
Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.
Topics: Adiponectin; Adolescent; Body Mass Index; Body Size; Child; China; Exercise Therapy; Feeding Behavio | 2007 |
Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity.
Topics: Acanthosis Nigricans; Adolescent; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; G | 2006 |
Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Topics: Adolescent; Analysis of Variance; Behavior Therapy; Body Mass Index; Child; Combined Modality Therap | 2007 |
[Insulin resistance in type 2 diabetes patients].
Topics: Aged; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothel | 2007 |
The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin.
Topics: Adult; Cohort Studies; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metabolic Syndrome; Me | 2008 |
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Anticholesteremic Agents; Base Sequence; Cell | 2008 |